CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10272117,102721173,3,F,20130815,20180419,20140702,20180517,PER,,US-009507513-1406USA009400,MERCK,,18,YR,,F,Y,,,20180517,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,102721173,1,Product used for unknown indication
10968837,109688372,2,F,,20180530,20150331,20180614,EXP,,UG-CIPLA LTD.-2015UG02466,CIPLA,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G ET AL.,. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAFS. 2015",,,,,Y,,,20180614,,OT,UG,UG,EFAVIRENZ.,Blood creatinine increased;Lipodystrophy acquired,109688372,OT,,,109688372,1,2006,,,,109688372,1,HIV infection
11868354,118683546,6,F,20001221,20180322,20151224,20180403,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11527520,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20180403,,OT,FR,FR,EFAVIRENZ.,Gestational diabetes;Normal newborn;Pregnancy,118683546,OT,,,118683546,1,19970902,,,,118683546,1,Antiretroviral therapy
11937618,119376188,8,F,,20180427,20160122,20180507,EXP,,CA-009507513-1601CAN007640,MERCK,,54,YR,,M,Y,,,20180507,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,119376188,OT,,,,,,,,,119376188,1,Product used for unknown indication
12741534,127415344,4,F,,20180625,20160914,20180628,EXP,,CA-ROCHE-1829817,ROCHE,,,,,M,Y,,,20180628,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,127415344,OT,,,,,,,,,127415344,1,Product used for unknown indication
12985056,129850564,4,F,,20180201,20161129,20180422,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20180214,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,129850564,OT,,,,,,,,,129850564,1,HIV infection
13014538,130145386,6,F,,20180607,20161209,20180622,EXP,,PHHY2015BR064616,NOVARTIS,,,,,F,Y,54,KG,20180622,,CN,BR,BR,EFAVIRENZ.,Alopecia;Blood iron increased;Chills;Diarrhoea;Dizziness;Drug intolerance;Dysphagia;Haemoglobin abnormal;Inappropriate schedule of drug administration;Malaise;Nausea;Poisoning;Retching;Serum ferritin abnormal;Serum ferritin decreased;Serum ferritin increased;Vomiting;Weight increased;Wrong technique in product usage process,130145386,OT,,,,,,,,,130145386,1,Haemoglobinopathy
13081932,130819322,2,F,201612,20180327,20170103,20180402,EXP,,PHHY2014IN119925,NOVARTIS,,52,YR,,M,Y,,,20180402,,MD,IN,IN,EFAVIRENZ.,Drug level decreased;Eye haemorrhage;Fall;Hand fracture;Osteoporosis;Therapy non-responder;Varicella,130819322,OT,,,,,,,,,130819322,1,Chronic myeloid leukaemia
13274205,132742059,9,F,,20180604,20170227,20180613,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016053,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20180613,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742059,OT,,,132742059,1,201110,,,,132742059,1,HIV infection
13274215,132742155,5,F,,20180419,20170227,20180430,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20180430,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742155,OT,,,132742155,1,200909,,,,132742155,1,HIV infection
13278460,132784606,6,F,,20180531,20170228,20180608,EXP,,FR-009507513-1702FRA008506,MERCK,,32,YR,,F,Y,,,20180608,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132784606,OT,,,132784606,1,201007,,,,132784606,1,Contraception
13339761,133397616,6,F,,20180412,20170315,20180420,EXP,,FR-009507513-1702FRA008692,MERCK,,28,YR,,F,Y,,,20180420,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,133397616,OT,,,133397616,2,201206,,,,133397616,1,HIV infection
13614423,136144232,2,F,2015,20180411,20170606,20180426,EXP,,RO-AUROBINDO-AUR-APL-2017-35002,AUROBINDO,,28,YR,,F,Y,,,20180426,,OT,RO,RO,EFAVIRENZ.,Ballismus;Brain oedema;Central nervous system lesion;Cerebral toxoplasmosis;Intracranial mass;Loss of consciousness;Motor dysfunction;Product use issue;Treatment noncompliance,136144232,HO,,,136144232,1,2006,,,,136144232,1,HIV infection
13675730,136757303,3,F,20170518,20180403,20170621,20180411,EXP,,ZA-GILEAD-2017-0278617,GILEAD,,29,YR,A,M,Y,82.2,KG,20180411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicide attempt,136757303,HO,,,136757303,1,20140605,201705,,,136757303,1,HIV infection
13851390,138513902,2,F,,20180508,20170809,20180516,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069840,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20180516,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,138513902,OT,,,,,,,,,138513902,1,Product used for unknown indication
14107276,141072762,2,F,,20171005,20171018,20180530,EXP,,US-MYLANLABS-2017M1064617,MYLAN,BHOGAL S. TENOFOVIR-INDUCED FANCONI SYNDROME PRESENTING AS HYPOKALEMIC PERIODIC PARALYSIS. AM-J-THER 2017;24(5):E617-E618.,54,YR,,F,Y,,,20180530,,MD,US,US,EFAVIRENZ.,Fall;Fanconi syndrome acquired,141072762,OT,,,,,,,,,141072762,1,HIV infection
14118988,141189882,2,F,,20180625,20171024,20180627,EXP,,CA-ROCHE-2011375,ROCHE,,,,A,M,Y,,,20180627,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,141189882,OT,,,,,,,,,141189882,1,Product used for unknown indication
14145935,141459352,2,F,,20180420,20171031,20180430,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017166264,VIIV,,44,YR,,F,Y,,,20180430,,OT,DE,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,141459352,OT,,,,,,,,,141459352,1,HIV infection
14146006,141460062,2,F,,20180420,20171031,20180430,EXP,,ET-GLAXOSMITHKLINE-ET2017166264,GLAXOSMITHKLINE,,44,YR,,F,Y,,,20180430,,OT,DE,ET,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,141460062,OT,,,,,,,,,141460062,1,HIV infection
14246609,142466094,4,F,,20180426,20171204,20180510,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20180510,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142466094,OT,,,,,,,,,142466094,1,Cardiovascular event prophylaxis
14247661,142476616,6,F,,20180509,20171204,20180517,EXP,,GB-009507513-1711GBR010764,MERCK,,85,YR,,M,Y,,,20180517,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142476616,OT,,,,,,,,,142476616,1,Cardiovascular event prophylaxis
14248948,142489485,5,F,,20180330,20171204,20180410,EXP,,GB-MYLANLABS-2017M1075159,MYLAN,,85,YR,,M,Y,,,20180405,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142489485,OT,,,,,,,,,142489485,1,Cardiovascular event prophylaxis
14254383,142543838,8,F,,20180612,20171205,20180620,EXP,,GB-TEVA-2017-GB-828487,TEVA,,85,YR,,M,Y,,,20180620,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142543838,OT,,,,,,,,,142543838,1,Inflammatory bowel disease
14263156,142631565,5,F,,20180502,20171208,20180514,EXP,GB-MHRA-ADR 24247007,GB-LUPIN PHARMACEUTICALS INC.-2017-07065,LUPIN,,85,YR,,M,Y,,,20180514,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142631565,OT,,,,,,,,,142631565,1,Cardiovascular event prophylaxis
14265678,142656788,8,F,,20180503,20171208,20180515,EXP,,GB-BAUSCH-BL-2017-032451,BAUSCH AND LOMB,,85,YR,,M,Y,,,20180515,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142656788,OT,,,,,,,,,142656788,1,Inflammatory bowel disease
14277495,142774952,2,F,,20180328,20171212,20180410,EXP,,GB-SHIRE-GB201732945,SHIRE,,,,,,Y,,,20180410,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142774952,OT,,,,,,,,,142774952,1,Inflammatory bowel disease
14306973,143069733,3,F,,20180306,20171220,20180422,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20180319,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,143069733,OT,,,,,,,,,143069733,1,Bipolar disorder
14318289,143182892,2,F,,20180326,20171222,20180409,EXP,,GB-AUROBINDO-AUR-APL-2017-46472,AUROBINDO,,85,YR,,M,Y,,,20180409,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143182892,OT,,,,,,,,,143182892,1,Cardiovascular event prophylaxis
14339631,143396314,4,F,,20180421,20171230,20180505,EXP,,GB-AUROBINDO-AUR-APL-2017-48435,AUROBINDO,,,,C,,Y,,,20180505,,MD,GB,GB,Efavirenz Film-coated Tablet,Cognitive disorder;Diplegia;Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;HIV-associated neurocognitive disorder;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143396314,OT,,,,,,,,,143396314,1,Perinatal HIV infection
14363782,143637823,3,F,201404,20180615,20180108,20180625,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098391,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20180625,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,143637823,OT,,,,,,,,,143637823,1,HIV infection
14367906,143679063,3,F,2015,20180611,20180109,20180625,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-118541,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,57,KG,20180625,,MD,FR,FR,SUSTIVA,General physical condition abnormal;Hypermetabolism;Pulmonary mass;Virologic failure,143679063,HO,,,143679063,3,20151117,,,,143679063,1,HIV infection
14371508,143715082,2,F,20171107,20180503,20180110,20180508,EXP,GB-MHRA-EYC 00171403,GB-VIIV HEALTHCARE LIMITED-GB2018001376,VIIV,,47,YR,,F,Y,,,20180508,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143715082,HO,,,143715082,1,20170501,20171216,,,143715082,1,HIV infection
14371647,143716472,2,F,20171107,20180503,20180110,20180508,EXP,GB-MHRA-EYC 00171403,GB-GLAXOSMITHKLINE-GB2018001376,GLAXOSMITHKLINE,,47,YR,,F,Y,,,20180508,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143716472,LT,,,143716472,1,20170501,20171216,,,143716472,1,HIV infection
14379004,143790042,2,F,,20180226,20180112,20180413,PER,,GB-LUPIN PHARMACEUTICALS INC.-2017-07518,LUPIN,,,,N,M,Y,1.8,KG,20180413,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby,,,,,,,,,,,143790042,1,Product used for unknown indication
14398660,143986607,7,F,20171107,20180508,20180117,20180522,EXP,GB-MHRA-EYC 00171403,GB-LUPIN PHARMACEUTICALS INC.-2018-00076,LUPIN,,47,YR,,F,Y,,,20180522,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143986607,LT,,,143986607,1,20170501,20171216,,,143986607,1,HIV infection
14432315,144323152,2,F,,20180411,20180124,20180418,EXP,,GB-TEVA-2017-GB-837322,TEVA,,,,,,Y,,,20180418,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,144323152,OT,,,,,,,,,144323152,1,Cardiovascular event prophylaxis
14474087,144740872,2,F,,20180117,20180201,20180422,EXP,,US-APOTEX-2018AP006304,APOTEX,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE DOI: 10.1177/2325957417729751. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (6):540-545",43,YR,,M,Y,,,20180201,,MD,US,US,EFAVIRENZ.,Coccidioidomycosis;Condition aggravated;Immune reconstitution inflammatory syndrome,144740872,OT,,,,,,,,,144740872,1,Antiretroviral therapy
14475215,144752158,8,F,,20180510,20180201,20180529,EXP,,IE-SA-2017SA124549,SANOFI AVENTIS,,37,YR,A,F,Y,,,20180529,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Skin atrophy,144752158,OT,,,,,,,,,144752158,1,Cutaneous sarcoidosis
14499394,144993946,6,F,,20180512,20180207,20180523,EXP,,IE-BAUSCH-BL-2018-002757,BAUSCH AND LOMB,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017 JUN 01;76(6)(1):AB216.",37,YR,,F,Y,,,20180523,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective for unapproved indication;Leukopenia;Off label use;Product use in unapproved indication;Skin atrophy,144993946,OT,,,,,,,,,144993946,1,Cutaneous sarcoidosis
14514940,1451494012,12,F,,20180608,20180209,20180622,EXP,,IE-CONCORDIA PHARMACEUTICALS INC.-E2B_00009781,CONCORDIA,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. J AM ACAD DERMATOL. 2017 JUN 01;76(6 SUPPL 1):AB216.",37,YR,,F,Y,,,20180622,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Drug ineffective for unapproved indication;Leukopenia;Off label use;Product use in unapproved indication;Skin atrophy,1451494012,OT,,,,,,,,,1451494012,1,Cutaneous sarcoidosis
14527089,145270894,4,F,,20180618,20180213,20180627,EXP,,IE-MYLANLABS-2018M1009569,MYLAN,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M.. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY.. 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;76(6 SUPPL 1):AB216",37,YR,,F,Y,,,20180627,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Skin atrophy,145270894,OT,,,,,,,,,145270894,1,Sarcoidosis
14553441,145534415,5,F,20171107,20180613,20180220,20180621,EXP,GB-MHRA-EYC 00171403,GB-TEVA-2018-GB-857839,TEVA,,47,YR,,F,Y,,,20180621,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,145534415,HO,,,145534415,1,20170501,20171216,,,145534415,1,HIV infection
14593102,145931022,2,F,2016,20180406,20180302,20180411,EXP,,TR-GILEAD-2018-0322921,GILEAD,,58,YR,A,M,Y,108,KG,20180411,,MD,TR,TR,EFAVIRENZ.,Bone density decreased;Nephrolithiasis;Renal impairment,145931022,OT,,,145931022,1,2013,2015,,,145931022,1,HIV infection
14595957,145959576,6,F,,20180524,20180303,20180531,EXP,,FR-AUROBINDO-AUR-APL-2018-010835,AUROBINDO,,,,,,Y,,,20180601,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145959576,OT,,,145959576,1,20111001,,,,145959576,1,HIV infection
14596238,145962383,3,F,,20180528,20180303,20180610,EXP,,FR-AUROBINDO-AUR-APL-2018-010672,AUROBINDO,,32,YR,,F,Y,,,20180611,,OT,US,FR,EFAVIRENZ.,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145962383,OT,,,145962383,1,20090901,,,,145962383,1,HIV infection
14604016,146040164,4,F,,20180509,20180306,20180516,EXP,,IE-LEO PHARMA-307607,LEO PHARM,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;76(6 SUPPL 1):AB216.",37,YR,,F,Y,,,20180516,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective for unapproved indication;Leukopenia;Product use in unapproved indication;Skin atrophy,146040164,OT,,,,,,,,,146040164,1,Sarcoidosis
14606158,146061582,2,F,20180121,20180220,20180307,20180422,EXP,,US-APOTEX-2018AP007209,APOTEX,,60,YR,,M,Y,64,KG,20180306,,CN,JP,US,EFAVIRENZ.,Respiratory distress,146061582,DE,,,146061582,1,20171130,,,,146061582,1,Tuberculosis
14619562,146195624,4,F,20001221,20180322,20180309,20180403,EXP,,FR-AUROBINDO-AUR-APL-2018-011998,AUROBINDO,,37,YR,,F,Y,,,20180403,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn;Pregnancy,146195624,OT,,,146195624,1,19960814,,,,146195624,1,Antiretroviral therapy
14638395,146383952,2,F,,20180515,20180314,20180521,PER,,US-PFIZER INC-2016481048,PFIZER,,87,YR,,M,Y,,,20180521,,OT,US,US,SUSTIVA,Neoplasm progression,,,,,,,,,,,146383952,1,Metastatic renal cell carcinoma
14649319,146493192,2,F,,20180302,20180316,20180422,EXP,,CA-APOTEX-2018AP006359,APOTEX,,45,YR,,M,Y,,,20180316,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,146493192,OT,,,,,,,,,146493192,1,HIV infection
14651092,146510923,3,F,,20180423,20180316,20180426,EXP,FR-EMA-20170316-SROYP-090824780,FR-GILEAD-2016-0216060,GILEAD,,32,YR,A,F,Y,,,20180426,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,146510923,OT,,,146510923,4,201007,,,,146510923,1,HIV infection
14652614,146526142,2,F,,20180304,20180319,20180422,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20180319,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146526142,OT,,,,,,,,,146526142,1,Psychotic disorder
14654041,1465404112,12,F,,20180608,20180319,20180618,EXP,,PHHY2018IE041144,ALCON,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M.. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY.. 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;76(6SUPPL1):AB216",37,YR,,F,Y,,,20180618,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Skin atrophy,1465404112,OT,,,,,,,,,1465404112,1,Sarcoidosis
14666305,146663053,3,F,,20180403,20180321,20180409,EXP,FR-EMA-20170404-RENITAROYP-155219665,FR-GILEAD-2016-0216062,GILEAD,,28,YR,A,F,Y,,,20180409,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,146663053,OT,,,146663053,1,201110,,,,146663053,1,HIV infection
14674924,146749243,3,F,20180304,20180405,20180323,20180420,EXP,,CO-AUROBINDO-AUR-APL-2018-016866,AUROBINDO,,26,YR,,M,Y,105,KG,20180420,,PH,CO,CO,Efavirenz 600mg,Arthralgia;Diarrhoea;Headache;Pyrexia;Treatment noncompliance;Vomiting,146749243,HO,,,146749243,1,20180226,,,,146749243,1,HIV infection
14682623,146826233,3,F,20180313,20180326,20180327,20180409,EXP,,ZA-AUROBINDO-AUR-APL-2018-015610,AUROBINDO,,35,YR,,F,Y,,,20180409,,OT,ZA,ZA,EFAVIRENZ.,Cardiac murmur,146826233,OT,,,146826233,1,20180214,,,,146826233,1,Product used for unknown indication
14683821,146838212,2,F,2017,20180326,20180327,20180411,PER,,"US-THERATECHNOLOGIES, INC.-TH-2018-00226",THERATECHNOLOGIES,,,,,,Y,,,20180411,,CN,US,US,SUSTIVA,HIV test positive,,,,,146838212,1,201105,,,,146838212,1,HIV infection
14689574,146895745,5,F,,20180510,20180328,20180517,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-007426,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20180517,,OT,GB,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Product use in unapproved indication;Skin atrophy,146895745,OT,,,,,,,,,146895745,1,Sarcoidosis
14703627,147036271,1,I,19991102,20010702,20180402,20180402,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-10902104,BRISTOL MYERS SQUIBB,,24,YR,,M,Y,,,20180402,,OT,US,JP,EFAVIRENZ.,Anaemia;Hypokalaemia,147036271,LT,,,147036271,1,19991020,19991102,,,147036271,1,Acquired immunodeficiency syndrome
14703977,147039772,2,F,,20180504,20180402,20180511,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018GSK054286,VIIV,,20,YR,,F,Y,,,20180511,,CN,US,BR,ESTOCRIN (EFAVIRENZ),Bacterial vaginosis;Blepharospasm;Blood pressure increased;Exposure during pregnancy;Gait disturbance;Headache;Live birth;Paraesthesia;Syphilis;Vision blurred,147039772,OT,,,147039772,1,20171208,,,,147039772,1,HIV infection
14705040,147050401,1,I,,20180327,20180402,20180402,EXP,,US-JNJFOC-20180341027,JANSSEN,"DEAN R, SUBEDI R, KARKEE A. CHYLOUS ASCITES IN INTRA-ABDOMINAL MYCOBACTERIUM AVIUM COMPLEX IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. JOURNAL OF INVESTIGATIVE MEDICINE 2018;66(2):457.",51,YR,A,M,Y,,,20180402,,OT,US,US,EFAVIRENZ.,Ascites;Mycobacterium avium complex immune restoration disease,147050401,OT,,,,,,,,,147050401,1,Acquired immunodeficiency syndrome
14705105,147051053,3,F,20170920,20180523,20180402,20180604,EXP,,ZA-MYLANLABS-2018M1021064,MYLAN,,47,YR,,M,Y,44.8,KG,20180602,,MD,ZA,ZA,EFAVIRENZ.,Psoas abscess,147051053,HO,,,147051053,1,20170405,20170908,,,147051053,1,Tuberculosis
14711202,147112022,2,F,,20180416,20180403,20180424,EXP,,FR-GILEAD-2018-0323412,GILEAD,,54,YR,A,M,Y,,,20180424,,OT,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Nephropathy toxic;Renal tubular dysfunction,147112022,OT,,,,,,,,,147112022,1,HIV infection
14711220,147112201,1,I,,20180329,20180403,20180403,EXP,,US-GILEAD-2018-0330613,GILEAD,,24,YR,A,F,Y,,,20180403,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Disability,147112201,DS,,,147112201,1,20150202,,,,147112201,1,HIV infection
14713651,147136511,1,I,20171227,20180320,20180404,20180404,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018012149,MACLEODS,,,,,,Y,,,20180404,,CN,US,US,EFAVIRENZ.,Chest pain;Electrocardiogram QT prolonged;Incorrect drug administration duration,147136511,LT,,,147136511,1,20170330,20171227,,,147136511,1,Pulmonary tuberculosis
14715497,147154971,1,I,,20180322,20180404,20180404,EXP,,FR-MYLANLABS-2018M1020400,MYLAN,,28,YR,,F,Y,,,20180331,,CN,US,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,147154971,OT,,,,,,,,,147154971,1,HIV infection
14715558,147155582,2,F,,20180402,20180404,20180410,EXP,,TR-GILEAD-2018-0329488,GILEAD,,45,YR,A,F,Y,,,20180410,,MD,TR,TR,EFAVIRENZ.,Anxiety disorder;Blood HIV RNA increased;Drug ineffective;Multiple-drug resistance;Off label use,147155582,OT,,,147155582,1,2011,,,,147155582,1,HIV infection
14715667,147156671,1,I,201607,20161115,20180404,20180404,PER,,US-VIFOR (INTERNATIONAL) INC.-VIT-2016-08052,VIFOR,,60,YR,,M,Y,,,20180404,,CN,US,US,SUSTIVA,Burning sensation;Drug dose omission;Rash pruritic;Skin haemorrhage,,,,,147156671,1,20160727,,,,147156671,1,Hyperkalaemia
14719430,147194301,1,I,,20180321,20180405,20180405,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-027036,BRISTOL MYERS SQUIBB,,,,,F,Y,63.5,KG,20180405,,CN,US,US,SUSTIVA,Adverse event;Drug screen positive,,,,,147194301,1,2010,201712,,,147194301,1,HIV infection
14726637,147266371,1,I,,20180323,20180406,20180406,EXP,,IT-CIPLA LTD.-2018IT14717,CIPLA,,,,,,Y,,,20180406,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Gastrointestinal disorder;Treatment noncompliance;Virologic failure,147266371,OT,,,,,,,,,147266371,1,HIV infection
14727479,147274791,1,I,,20180330,20180406,20180406,EXP,,FR-JNJFOC-20180402054,JANSSEN,,,,A,F,Y,57,KG,20180406,,MD,FR,FR,EFAVIRENZ.,Hospitalisation;Treatment noncompliance,147274791,HO,,,,,,,,,147274791,1,HIV infection
14727861,147278611,1,I,,20180209,20180406,20180406,EXP,,BR-MYLANLABS-2018M1011905,MYLAN,,31,YR,,F,Y,,,20180406,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Abortion spontaneous;Exposure during pregnancy,147278611,OT,,,147278611,1,20150727,,,,147278611,1,Product used for unknown indication
14728431,147284311,1,I,201603,20180328,20180406,20180406,EXP,,CO-009507513-1803COL013075,MERCK,,26,YR,,M,Y,,,20180406,,MD,CO,CO,EFAVIRENZ.,Autoimmune hepatitis;Autoimmune thyroiditis;Thrombocytopenia,147284311,HO,,,147284311,1,201603,201603,,,147284311,1,HIV infection
14732971,147329711,1,I,,20180405,20180409,20180409,EXP,,US-STRIDES ARCOLAB LIMITED-2018SP002641,STRIDES,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP. 2018;4(3):256-258",,,,,Y,,,20180409,,MD,US,US,EFAVIRENZ.,Drug hypersensitivity;Lichenoid keratosis;Pruritus;Rash erythematous;Skin hyperpigmentation;Skin plaque,147329711,OT,,,,,,,,,147329711,1,HIV infection
14735340,147353401,1,I,,20180327,20180409,20180409,EXP,,US-MYLANLABS-2018M1022043,MYLAN,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP 2018;4(3):256-258.",4,DEC,,M,Y,,,20180409,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,147353401,OT,,,,,,,,,147353401,1,HIV infection
14737618,147376181,1,I,,20180327,20180409,20180409,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-029837,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20180409,,OT,US,ZA,EFAVIRENZ.,Drug eruption,147376181,OT,,,,,,,,,147376181,1,HIV infection
14738191,147381912,2,F,20171215,20180411,20180409,20180417,EXP,,FR-GILEAD-2018-0324258,GILEAD,,33,YR,A,M,Y,62.5,KG,20180417,,MD,FR,FR,EFAVIRENZ.,Hepatitis A,147381912,HO,,,147381912,1,20150616,201711,,,147381912,1,HIV infection
14740218,147402181,1,I,,20180402,20180410,20180410,EXP,,US-HETERO CORPORATE-HET2018US00298,HETERO,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD-CASE-REP. 2018;4(3):256-258",40,YR,,M,Y,,,20180410,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,147402181,OT,,,,,,,,,147402181,1,HIV infection
14741655,147416551,1,I,,20171214,20180410,20180410,EXP,,DE-GLAXOSMITHKLINE-DE2017193216,GLAXOSMITHKLINE,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES. A DECADE LONGITUDINAL STUDY.. 2017;19:12,28,YR,,M,Y,,,20180410,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147416551,OT,,,,,,,,,147416551,1,Product used for unknown indication
14741759,147417591,1,I,,20171214,20180410,20180410,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2017193216,VIIV,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES. A DECADE LONGITUDINAL STUDY.. 2017;19:12,28,YR,,M,Y,,,20180410,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147417591,OT,,,,,,,,,147417591,1,Product used for unknown indication
14746800,147468001,1,I,,20171214,20180411,20180411,EXP,,DE-GLAXOSMITHKLINE-DE2017193260,GLAXOSMITHKLINE,LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES. A DECADE LONGITUDINAL STUDY. 2017;12:10,43,YR,,F,Y,,,20180411,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147468001,OT,,,,,,,,,147468001,1,Product used for unknown indication
14746801,147468011,1,I,,20171214,20180411,20180411,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2017193260,VIIV,LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES. A DECADE LONGITUDINAL STUDY. 2017;12:10,43,YR,,F,Y,,,20180411,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147468011,OT,,,,,,,,,147468011,1,Product used for unknown indication
14750868,147508681,1,I,,20171214,20180412,20180412,EXP,,DE-AUROBINDO-AUR-APL-2017-47615,AUROBINDO,,43,YR,,F,Y,,,20180412,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,147508681,OT,,,,,,,,,147508681,1,Product used for unknown indication
14751313,147513131,1,I,,20171214,20180412,20180412,EXP,,DE-AUROBINDO-AUR-APL-2017-47618,AUROBINDO,,28,YR,,M,Y,,,20180412,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147513131,OT,,,,,,,,,147513131,1,Product used for unknown indication
14756319,147563191,1,I,,20180409,20180413,20180413,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018GSK063417,VIIV,,46,YR,,M,Y,,,20180413,,MD,GB,GB,EFAVIRENZ.,Renal failure,147563191,OT,,,,,,,,,147563191,1,HIV infection
14756367,147563671,1,I,,20180409,20180413,20180413,EXP,,GB-GLAXOSMITHKLINE-GB2018GSK063417,GLAXOSMITHKLINE,,46,YR,,M,Y,,,20180413,,MD,GB,GB,EFAVIRENZ.,Renal failure,147563671,OT,,,,,,,,,147563671,1,HIV infection
14758880,147588801,1,I,,20180405,20180413,20180413,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018058111,VIIV,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20180413,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,147588801,OT,,,,,,,,,147588801,1,Perinatal HIV infection
14758881,147588811,1,I,,20180405,20180413,20180413,EXP,,GB-GLAXOSMITHKLINE-GB2018058111,GLAXOSMITHKLINE,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20180413,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,147588811,OT,,,,,,,,,147588811,1,Perinatal HIV infection
14759551,147595511,1,I,,20171214,20180413,20180413,EXP,,DE-GLAXOSMITHKLINE-DE2017193261,GLAXOSMITHKLINE,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES.. A DECADE LONGITUDINAL STUDY. 2017;12:10,25,YR,,F,Y,,,20180413,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147595511,OT,,,,,,,,,147595511,1,Product used for unknown indication
14759552,147595521,1,I,,20171214,20180413,20180413,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2017193261,VIIV,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES.. A DECADE LONGITUDINAL STUDY. 2017;12:10,25,YR,,F,Y,,,20180413,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147595521,OT,,,,,,,,,147595521,1,Product used for unknown indication
14759637,147596371,1,I,20140810,20180406,20180413,20180413,EXP,,IT-ABBVIE-18S-083-2316572-00,ABBVIE,,51,YR,,F,Y,48,KG,20180413,,OT,IT,IT,EFAVIRENZ.,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,147596371,OT,,,147596371,3,20120627,20141110,,,147596371,1,HIV infection
14760281,147602811,1,I,,20180402,20180414,20180414,EXP,,GB-MICRO LABS LIMITED-BB2018-00506,MICRO LABS,,85,YR,,M,Y,,,20180414,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,147602811,OT,,,,,,,,,147602811,1,Cardiovascular event prophylaxis
14767950,147679501,1,I,,20180404,20180417,20180417,EXP,,ZA-MYLANLABS-2018M1024536,MYLAN,,,,,F,Y,59,KG,20180417,,MD,ZA,ZA,EFAVIRENZ.,Depression;Fatigue;Maternal exposure during pregnancy;Seizure;Treatment noncompliance,147679501,OT,,,147679501,1,20170117,,,,147679501,1,Tuberculosis
14768054,147680542,2,F,,20180411,20180417,20180424,EXP,,ES-LUPIN PHARMACEUTICALS INC.-2018-02907,LUPIN,,57,YR,,M,Y,,,20180424,,OT,ES,ES,EFAVIRENZ.,Fatigue;Renal impairment;Somnolence;Toxicity to various agents,147680542,OT,,,147680542,1,2010,,,,147680542,1,Partial seizures
14771975,147719751,1,I,2016,20160701,20180417,20180417,EXP,,US-VIFOR (INTERNATIONAL) INC.-VIT-2016-03465,VIFOR,,66,YR,,M,Y,83.99,KG,20180417,,,COUNTRY NOT SPECIFIED,US,SUSTIVA,Musculoskeletal pain;Musculoskeletal stiffness;Pain in extremity;Radiculitis brachial;Thrombosis,147719751,OT,,,147719751,1,20160606,,,,147719751,1,Hyperkalaemia
14772020,147720201,1,I,,20180410,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066160,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Renal injury,147720201,OT,,,,,,,,,147720201,1,HIV infection
14772021,147720211,1,I,,20180410,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK063154,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720211,OT,,,,,,,,,147720211,1,HIV infection
14772025,147720251,1,I,,20180410,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066151,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Liver injury,147720251,OT,,,,,,,,,147720251,1,HIV infection
14772031,147720311,1,I,,20180410,20180417,20180417,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK066150,GLAXOSMITHKLINE,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720311,OT,,,,,,,,,147720311,1,HIV infection
14772032,147720321,1,I,,20180410,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066160,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Renal injury,147720321,OT,,,,,,,,,147720321,1,HIV infection
14772033,147720331,1,I,,20180410,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK063154,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720331,OT,,,,,,,,,147720331,1,HIV infection
14772034,147720341,1,I,,20180410,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066151,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Liver injury,147720341,OT,,,,,,,,,147720341,1,HIV infection
14772040,147720401,1,I,,20180410,20180417,20180417,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK066150,VIIV,"LUO X-L, MO L-D, WEI Z-M, SU G-S, HUANG J-P, WU J-Y. STUDY OF CURATIVE EFFECT ACCURACY AMONG 3 GROUPS OF COMMONLY USED ANTI-HIV DRUGS. INFECT DIS INFO. 2017;30:342-383",,,,,Y,,,20180417,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,147720401,OT,,,,,,,,,147720401,1,HIV infection
14772166,147721661,1,I,,20180403,20180418,20180418,EXP,,GB-AUROBINDO-AUR-APL-2018-020351,AUROBINDO,,,,C,,Y,,,20180418,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,147721661,OT,,,,,,,,,147721661,1,Perinatal HIV infection
14773305,147733051,1,I,,20171214,20180418,20180418,EXP,,DE-AUROBINDO-AUR-APL-2017-47616,AUROBINDO,,25,YR,,F,Y,,,20180418,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,147733051,OT,,,,,,,,,147733051,1,Product used for unknown indication
14776155,147761552,2,F,,20180411,20180418,20180420,EXP,,US-GILEAD-2018-0333115,GILEAD,,54,YR,A,M,Y,,,20180420,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Hip arthroplasty;Thrombosis,147761552,OT,,,147761552,2,2018,,,,147761552,1,HIV infection
14776657,147766571,1,I,20160329,20160405,20180419,20180419,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026039,BRISTOL MYERS SQUIBB,,53,YR,,F,Y,54,KG,20180419,,MD,UG,UG,EFAVIRENZ.,Cardiac arrest;Electrolyte imbalance;Gastritis;Helicobacter test positive;Malnutrition;Oesophageal carcinoma;Oral candidiasis,147766571,OT,,,147766571,1,20120705,20160329,,,147766571,1,HIV infection
14778397,147783971,1,I,,20180411,20180419,20180419,EXP,,PHHY2018ES064491,SANDOZ,"FERNANDEZ MC, ROIG JR, SANCHEZ EC, CENTELLAS FM, BONNIN RR, PADRO SJ ET AL.. SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED.. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2018;25:PP A123",57,YR,,M,Y,,,20180419,,OT,ES,ES,EFAVIRENZ.,Fatigue;Renal impairment;Somnolence;Toxicity to various agents,147783971,OT,,,147783971,1,2010,2013,,,147783971,1,Partial seizures
14779252,147792522,2,F,,20180405,20180419,20180422,EXP,,ES-APOTEX-2018AP010988,APOTEX,"MARINO FERNANDEZ C., JUVANY ROIG R., ESTEBAN SANCHEZ C., FALIP CENTELLAS M., RIGO BONNIN R., SALA PADRO J., JODAR MASANES R.. SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2018;25 (1):A123",57,YR,,M,Y,,,20180419,,OT,ES,ES,EFAVIRENZ.,Fatigue;Intentional overdose;Renal impairment;Somnolence;Toxicity to various agents,147792522,OT,,,147792522,2,201609,,,,147792522,1,Epilepsy
14781533,147815332,2,F,,20180522,20180420,20180601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035189,BRISTOL MYERS SQUIBB,,47,YR,,F,Y,109,KG,20180601,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147815332,HO,,,147815332,1,20161004,20171215,,,147815332,1,HIV infection
14782075,147820751,1,I,,20180406,20180420,20180420,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035829,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180420,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myasthenia gravis,147820751,OT,,,,,,,,,147820751,1,HIV infection
14782122,147821221,1,I,,20180406,20180420,20180420,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035832,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180420,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Sarcoidosis,147821221,OT,,,,,,,,,147821221,1,HIV infection
14782138,147821381,1,I,,20180406,20180420,20180420,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035835,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180420,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune thrombocytopenic purpura,147821381,OT,,,,,,,,,147821381,1,HIV infection
14784717,147847171,1,I,,20180409,20180420,20180420,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035345,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20180420,,OT,BR,PT,EFAVIRENZ.,Pemphigoid,147847171,HO,,,,,,,,,147847171,1,HIV infection
14785160,147851601,1,I,,20180416,20180420,20180420,EXP,,ES-TEVA-2018-ES-884771,TEVA,"MARINO FERNANDEZ C, JUVANY ROIG R, ESTEBAN SANCHEZ C, FALIP CENTELLAS M, RIGO BONNIN R, SALA PADRO J, ET AL. SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED. EJHP-SP 2018;25 (SUPPL. 1):A123 ABSTR. 175.",57,YR,,M,Y,,,20180420,,OT,ES,ES,EFAVIRENZ.;Tenofovir/efavirenz/emtricitabine,Fatigue;Poisoning;Somnolence,147851601,OT,,,147851601,2,201609,,,,147851601,1,Partial seizures
14788887,147888871,1,I,,20180408,20180423,20180423,EXP,,ES-AUROBINDO-AUR-APL-2018-021230,AUROBINDO,BARRUFET P.. EXPERIENCIA CON GENVOYA VIDA REAL PACIENTE PRETRATO. PRESENTATION.,46,YR,,,Y,,,20180423,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,147888871,OT,,,147888871,2,200805,,,,147888871,1,HIV infection
14790646,147906461,1,I,,20180413,20180423,20180423,EXP,,PT-MYLANLABS-2018M1025394,MYLAN,"NUNES C, ROCHA S, ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011;27:458-64",27,YR,,F,Y,,,20180423,,MD,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,147906461,OT,,,,,,,,,147906461,1,HIV infection
14793964,147939641,1,I,,20180418,20180423,20180423,EXP,GB-MHRA-EYC 00171779,GB-GLAXOSMITHKLINE-GB2018067264,GLAXOSMITHKLINE,,47,YR,,F,Y,109,KG,20180423,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147939641,OT,,,147939641,1,20170418,20171215,,,147939641,1,HIV infection
14794086,147940861,1,I,,20180418,20180423,20180423,EXP,GB-MHRA-EYC 00171779,GB-VIIV HEALTHCARE LIMITED-GB2018067264,VIIV,,47,YR,,F,Y,109,KG,20180423,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,147940861,HO,,,147940861,1,20170418,20171215,,,147940861,1,HIV infection
14794550,147945501,1,I,,20180411,20180423,20180423,EXP,,ES-MYLANLABS-2018M1025040,MYLAN,"MARINO FERNANDEZ C, JUVANY ROIG R, ESTEBAN SANCHEZ C, FALIP CENTELLAS M, RIGO BONNIN R, SALA PADRO J, ET AL. SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED. EJHP-SP 2018;25 (SUPPL. 1):A123 ABSTR. 175.",57,YR,,M,Y,,,20180423,,OT,ES,ES,EFAVIRENZ.;TENOFOVIR + EFAVIRENZ + EMTRICITABINE,Fatigue;Poisoning;Somnolence,147945501,OT,,,147945501,2,201609,,,,147945501,1,Partial seizures
14794849,147948491,1,I,,20180413,20180423,20180423,EXP,,FR-MYLANLABS-2018M1025689,MYLAN,,35,YR,,M,Y,,,20180423,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,No adverse event;Treatment failure,147948491,OT,,,,,,,,,147948491,1,HIV infection
14797476,147974761,1,I,20170610,20180213,20180424,20180424,PER,GB-MHRA-EYC 00173678,GB-LUPIN PHARMACEUTICALS INC.-2018-01261,LUPIN,,55,YR,,F,Y,,,20180424,,CN,GB,GB,SUSTIVA,Headache;Product substitution issue,,,,,147974761,1,20170601,20180131,,,147974761,1,HIV infection
14797478,147974781,1,I,,20180115,20180424,20180424,PER,,US-LUPIN PHARMACEUTICALS INC.-2018-00403,LUPIN,,,,A,M,Y,,,20180424,,OT,US,US,EFAVIRENZ.,Acute kidney injury,147974781,OT,,,147974781,3,20141101,,,,147974781,1,HIV infection
14798062,147980621,1,I,,20180406,20180424,20180424,EXP,,ES-UCBSA-2018015790,UCB,"DOI: 10.1136/EJHPHARM-2018-EAHPCONF.265#. FERNANDEZ CM, ROIG RJ, SANCHEZ CE, CENTELLAS MF, BONNIN RR, PADRO JS, ET AL.. SAFE USE OF LEVETIRACETAM AT DOSES HIGHER THAN THE MAXIMUM RECOMMENDED. 23RD CONGRESS OF THE EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS, (EAHP), 2018; SWEDAN. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2018;25 (SUPPL 1):A123",57,YR,,M,Y,,,20180424,,OT,ES,ES,EFAVIRENZ AND EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE;EFAVIRENZ.,Fatigue;Overdose;Renal impairment;Somnolence;Toxicity to various agents,147980621,OT,,,147980621,1,2010,2013,,,147980621,1,Partial seizures
14800764,148007643,3,F,20001221,20180529,20180424,20180607,EXP,,FR-MYLANLABS-2018M1025782,MYLAN,,37,YR,,F,Y,,,20180607,,OT,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,148007643,OT,,,148007643,1,19960814,,,,148007643,1,Antiretroviral therapy
14801460,148014601,1,I,2012,20180413,20180424,20180424,EXP,,GB-MYLANLABS-2018M1025061,MYLAN,,59,YR,,F,Y,,,20180420,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,148014601,OT,,,,,,,,,148014601,1,HIV infection
14804156,148041562,2,F,,20180525,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16566,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041562,OT,,,,,,,,,148041562,1,HIV infection
14804157,148041572,2,F,,20180525,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16560,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041572,OT,,,,,,,,,148041572,1,HIV infection
14804170,148041702,2,F,,20180525,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16562,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148041702,OT,,,,,,,,,148041702,1,HIV infection
14804712,148047122,2,F,,20180525,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16559,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148047122,OT,,,,,,,,,148047122,1,HIV infection
14804725,148047252,2,F,,20180525,20180425,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16565,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148047252,OT,,,,,,,,,148047252,1,HIV infection
14812901,148129011,1,I,,20180412,20180426,20180426,EXP,,US-CIPLA (EU) LIMITED-2018US16683,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180426,,OT,US,US,EFAVIRENZ.,Blood creatinine increased,148129011,OT,,,,,,,,,148129011,1,HIV infection
14812908,148129081,1,I,,20180412,20180426,20180426,EXP,,US-CIPLA (EU) LIMITED-2018US16687,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180426,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Blood creatinine increased,148129081,OT,,,,,,,,,148129081,1,HIV infection
14813174,148131741,1,I,,20180411,20180426,20180426,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16563,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180426,,OT,ZA,ZA,EFAVIRENZ.,Treatment failure,148131741,OT,,,,,,,,,148131741,1,HIV infection
14813198,148131981,1,I,,20180411,20180426,20180426,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16557,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180426,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148131981,OT,,,,,,,,,148131981,1,HIV infection
14814084,148140842,2,F,,20180525,20180426,20180525,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA16561,CIPLA,"MZINGWANE ML, TIEMESSEN CT, RICHTER KL, MAYAPHI SH, HUNT G AND BOWYER SM.. PRE-TREATMENT MINORITY HIV-1 DRUG RESISTANCE MUTATIONS AND LONG TERM VIROLOGICAL OUTCOMES: IS PREDICTION POSSIBLE?. VIROLOGY JOURNAL.. 2016;13:170",,,,,Y,,,20180525,,OT,ZA,ZA,EFAVIRENZ.,Virologic failure,148140842,OT,,,,,,,,,148140842,1,HIV infection
14814946,148149462,2,F,,20180426,20180426,20180509,EXP,,PE-MYLANLABS-2018M1026294,MYLAN,"GAMERO MT, GALLARDO MS, AGUILAR V, BRAVO E, GUEVARA J, MEJIA F. [NON-CIRRHOTIC PORTAL HYPERTENSION DUE TO DIDANOSINA. A RARE CASE]. REV-GASTROENTEROL-PERU 2017;37(1):87-90.",39,YR,,F,Y,,,20180509,,OT,PE,PE,EFAVIRENZ.,Ascites;Non-cirrhotic portal hypertension;Normocytic anaemia;Upper gastrointestinal haemorrhage,148149462,DE,,,,,,,,,148149462,1,HIV infection
14816449,148164492,2,F,201606,20180424,20180426,20180504,EXP,,TR-GILEAD-2018-0334419,GILEAD,,37,YR,A,M,Y,,,20180504,,MD,TR,TR,EFAVIRENZ.,Cardiac arrest;Low density lipoprotein increased;Myocardial infarction,148164492,HO,,,148164492,1,2010,2011,,,148164492,1,HIV infection
14818100,148181001,1,I,,20180412,20180427,20180427,EXP,,US-CIPLA (EU) LIMITED-2018US16684,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180427,,OT,US,US,EFAVIRENZ.,Blood creatinine abnormal,148181001,OT,,,,,,,,,148181001,1,HIV infection
14818477,148184771,1,I,,20180412,20180427,20180427,EXP,,US-CIPLA (EU) LIMITED-2018US16680,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180427,,OT,US,US,EFAVIRENZ.,Renal failure,148184771,OT,,,,,,,,,148184771,1,HIV infection
14819140,148191401,1,I,,20180206,20180427,20180427,EXP,,US-CIPLA LTD.-2018US05613,CIPLA,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE.. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (6):540 TO 545",,,,,Y,,,20180427,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Alopecia;Coccidioidomycosis;Death;Immune reconstitution inflammatory syndrome;Nervous system disorder;Transaminases increased,148191401,OT,,,,,,,,,148191401,1,HIV infection
14819851,148198511,1,I,,20180416,20180427,20180427,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035616,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20180427,,CN,GB,GB,EFAVIRENZ.,Renal failure,148198511,OT,,,,,,,,,148198511,1,Product used for unknown indication
14820568,148205681,1,I,,20180417,20180427,20180427,EXP,,ZA-MYLANLABS-2018M1026732,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",37,YR,,F,Y,,,20180427,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148205681,OT,,,,,,,,,148205681,1,HIV infection
14820971,148209711,1,I,,20180417,20180427,20180427,EXP,,ZA-MYLANLABS-2018M1026767,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180427,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148209711,OT,,,,,,,,,148209711,1,Product used for unknown indication
14820972,148209721,1,I,,20180417,20180427,20180427,EXP,,ZA-MYLANLABS-2018M1026768,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180427,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148209721,OT,,,,,,,,,148209721,1,Product used for unknown indication
14820973,148209731,1,I,,20180417,20180427,20180427,EXP,,ZA-MYLANLABS-2018M1026784,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180427,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148209731,OT,,,,,,,,,148209731,1,Product used for unknown indication
14821037,148210371,1,I,,20180414,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-022611,AUROBINDO,,46,YR,,M,Y,,,20180427,,MD,GB,GB,EFAVIRENZ.,Renal failure,148210371,OT,,,,,,,,,148210371,1,HIV infection
14821380,148213801,1,I,,20180402,20180427,20180427,EXP,,TR-GILEAD-2018-0331331,GILEAD,,57,YR,A,M,Y,,,20180427,,MD,TR,TR,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,148213801,OT,,,148213801,2,2016,,,,148213801,1,HIV infection
14821421,148214211,1,I,,20180413,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-023059,AUROBINDO,,,,,,Y,,,20180427,,OT,GB,GB,EFAVIRENZ.,Learning disorder;Psychotic symptom,148214211,OT,,,,,,,,,148214211,1,Perinatal HIV infection
14821530,148215301,1,I,,20180414,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-022596,AUROBINDO,,49,YR,,M,Y,,,20180427,,MD,GB,GB,EFAVIRENZ.,Virologic failure,148215301,OT,,,,,,,,,148215301,1,Product used for unknown indication
14822044,148220441,1,I,,20180414,20180427,20180427,EXP,,GB-AUROBINDO-AUR-APL-2018-022247,AUROBINDO,,47,YR,,F,Y,109,KG,20180427,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,148220441,HO,,,148220441,1,20161004,20171215,,,148220441,1,HIV infection
14826910,148269101,1,I,,20180416,20180430,20180430,EXP,,US-AUROBINDO-AUR-APL-2018-021805,AUROBINDO,,55,YR,,M,Y,,,20180430,,MD,US,US,EFAVIRENZ.,Cough;Erythema;Fatigue;Haematuria;Hepatosplenomegaly;Hypercalcaemia;Hyperphosphataemia;Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mycobacterium kansasii infection;Nephropathy toxic;Nodule;Pancytopenia;Papule;Pollakiuria;Pruritus;Skin lesion;Toxicity to various agents;Tubulointerstitial nephritis;Weight decreased,148269101,OT,,,148269101,1,2015,,,,148269101,1,HIV infection
14834074,148340741,1,I,20170823,20180419,20180501,20180501,EXP,GB-MHRA-EYC 00171579,GB-MYLANLABS-2018M1027953,MYLAN,,34,YR,,M,Y,84,KG,20180430,,PH,GB,GB,EFAVIRENZ.,Nightmare,148340741,OT,,,148340741,1,20170823,20171123,,,148340741,1,Acute HIV infection
14836583,148365833,3,F,201801,20180509,20180502,20180522,EXP,,ZA-CIPLA LTD.-2018ZA16946,CIPLA,,,,,,Y,,,20180522,,CN,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Liver injury;Musculoskeletal chest pain,148365833,OT,,,148365833,1,2013,,,,148365833,1,HIV infection
14836787,148367871,1,I,,20180417,20180502,20180502,EXP,,ZA-MYLANLABS-2018M1026786,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274",,,A,F,Y,,,20180502,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148367871,OT,,,,,,,,,148367871,1,Product used for unknown indication
14836788,148367881,1,I,,20180417,20180502,20180502,EXP,,ZA-MYLANLABS-2018M1026772,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180502,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148367881,OT,,,,,,,,,148367881,1,Product used for unknown indication
14836789,148367891,1,I,,20180417,20180502,20180502,EXP,,ZA-MYLANLABS-2018M1026775,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180502,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148367891,OT,,,,,,,,,148367891,1,Product used for unknown indication
14836790,148367901,1,I,,20180417,20180502,20180502,EXP,,ZA-MYLANLABS-2018M1026722,MYLAN,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J 2018;108(4):271-274.",,,A,F,Y,,,20180502,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Drug interaction;Encephalopathy;Toxicity to various agents,148367901,OT,,,,,,,,,148367901,1,Product used for unknown indication
14842808,148428081,1,I,,20180419,20180503,20180503,EXP,,PHHY2018ZA070112,SANDOZ,,,,A,F,Y,,,20180503,,OT,ZA,ZA,EFAVIRENZ.,Ataxia;Gait disturbance;Neuropsychiatric symptoms;Neurotoxicity;Psychomotor retardation,148428081,OT,,,,,,,,,148428081,1,Product used for unknown indication
14844449,148444491,1,I,201801,20180424,20180503,20180503,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2018GSK072426,VIIV,,47,YR,,M,Y,,,20180503,,MD,CL,CL,EFAVIRENZ.,Neutropenia;Primary syphilis;Pyrexia;Rash maculo-papular;Thrombocytopenia,148444491,OT,,,148444491,1,201801,201802,,,148444491,1,HIV test positive
14849889,148498893,3,F,2002,20180621,20180504,20180625,EXP,,PT-ABBVIE-18P-130-2343262-00,ABBVIE,"MARTINS S, QUINAZ C, XARA S, ET AL. AIDS  RELATED PRIMARY PULMONARY LYMPHOMA. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS. 2017;13 (3):142-145.",55,YR,,M,Y,,,20180625,,OT,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148498893,DE,,,148498893,4,1997,,,,148498893,1,HIV infection
14850446,148504461,1,I,,20180421,20180505,20180505,EXP,,FR-AUROBINDO-AUR-APL-2018-024204,AUROBINDO,,,,,,Y,,,20180505,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,148504461,OT,,,,,,,,,148504461,1,HIV infection
14850621,148506211,1,I,2009,20180420,20180506,20180506,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-037345,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20180506,,OT,FR,FR,EFAVIRENZ.,Inclusion body myositis,148506211,OT,,,148506211,1,1992,1995,,,148506211,1,HIV test positive
14853761,148537611,1,I,,20180424,20180507,20180507,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000675",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,,,Y,,,20180507,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148537611,HO,,,,,,,,,148537611,1,Prophylaxis
14853855,148538551,1,I,,20180424,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041530,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538551,OT,,,,,,,,,148538551,1,HIV infection
14853856,148538561,1,I,,20180424,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041531,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20180507,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538561,HO,,,,,,,,,148538561,1,HIV infection
14853857,148538571,1,I,,20180424,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041528,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148538571,OT,,,,,,,,,148538571,1,HIV infection
14854194,148541942,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039831,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Placental disorder;Product use issue;Stillbirth,148541942,OT,,,,,,,,,148541942,1,HIV infection
14854269,148542692,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041218,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Placental disorder;Product use issue;Stillbirth,148542692,OT,,,,,,,,,148542692,1,HIV infection
14854271,148542712,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041223,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148542712,OT,,,,,,,,,148542712,1,HIV infection
14854272,148542722,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041222,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148542722,OT,,,,,,,,,148542722,1,HIV infection
14854273,148542732,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041221,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Placental disorder;Product use issue;Stillbirth,148542732,OT,,,,,,,,,148542732,1,HIV infection
14854274,148542742,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041219,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Placental disorder;Product use issue;Stillbirth,148542742,OT,,,,,,,,,148542742,1,HIV infection
14854276,148542762,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041220,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Placental disorder;Product use issue;Stillbirth,148542762,OT,,,,,,,,,148542762,1,HIV infection
14854352,148543522,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041224,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148543522,OT,,,,,,,,,148543522,1,HIV infection
14854415,148544152,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041225,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148544152,OT,,,,,,,,,148544152,1,HIV infection
14854423,148544232,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041226,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148544232,OT,,,,,,,,,148544232,1,HIV infection
14854441,148544412,2,F,,20180509,20180507,20180522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041227,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180522,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,148544412,OT,,,,,,,,,148544412,1,HIV infection
14854677,148546771,1,I,,20180424,20180507,20180507,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041529,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180507,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148546771,OT,,,,,,,,,148546771,1,HIV infection
14858559,148585591,1,I,,20120615,20180508,20180508,PER,,US-009507513-1804USA011853,MERCK,,18,YR,,F,Y,,,20180508,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;No adverse event,,,,,,,,,,,,,
14858601,148586011,1,I,,20180424,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041526,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148586011,OT,,,,,,,,,148586011,1,HIV infection
14858605,148586051,1,I,,20180424,20180508,20180508,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041555,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180508,,OT,US,ZA,EFAVIRENZ.,Treatment failure,148586051,OT,,,,,,,,,148586051,1,HIV infection
14858764,148587641,1,I,,20180424,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039845,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148587641,OT,,,,,,,,,148587641,1,HIV infection
14858765,148587651,1,I,,20180424,20180508,20180508,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041527,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20180508,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,148587651,OT,,,,,,,,,148587651,1,HIV infection
14862937,148629371,1,I,,20180424,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039909,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629371,OT,,,,,,,,,148629371,1,Prophylaxis against HIV infection
14862938,148629381,1,I,,20180424,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041533,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629381,OT,,,,,,,,,148629381,1,Prophylaxis against HIV infection
14862940,148629401,1,I,,20180424,20180508,20180508,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041532,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180508,,OT,TH,TH,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,148629401,OT,,,,,,,,,148629401,1,Prophylaxis against HIV infection
14867714,148677141,1,I,,20180424,20180509,20180509,EXP,,ES-AUROBINDO-AUR-APL-2018-024616,AUROBINDO,,57,YR,,M,Y,,,20180509,,OT,ES,ES,EFAVIRENZ.;TENOFOVIR + EFAVIRENZ + EMTRICITABINE,Fatigue;Poisoning;Somnolence,148677141,OT,,,148677141,2,201609,,,,148677141,1,Partial seizures
14868582,148685822,2,F,20180413,20180615,20180509,20180621,EXP,,BR-STRIDES ARCOLAB LIMITED-2018SP003477,STRIDES,,,,,,Y,,,20180621,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,148685822,OT,,,,,,,,,148685822,1,Product used for unknown indication
14869524,148695242,2,F,2002,20180618,20180509,20180622,EXP,,PT-JNJFOC-20180508029,JANSSEN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO-CASTRO R. AIDS -RELATED PRIMARY PULMONARY LYMPHOMA. . REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS. 2017;13 (3):142-5.",55,YR,A,M,Y,,,20180622,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148695242,DE,,,148695242,3,1997,,,,148695242,1,HIV infection
14874621,148746211,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000678",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,A,F,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148746211,HO,,,,,,,,,148746211,1,Antibiotic prophylaxis
14874634,148746341,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000679",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,A,F,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148746341,HO,,,,,,,,,148746341,1,Antibiotic prophylaxis
14874652,148746521,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000676",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,A,F,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148746521,HO,,,,,,,,,148746521,1,Antibiotic prophylaxis
14874653,148746531,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000677",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,,,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148746531,HO,,,,,,,,,148746531,1,Antibiotic prophylaxis
14874710,148747101,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000680",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,,,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148747101,HO,,,,,,,,,148747101,1,Antibiotic prophylaxis
14874895,148748951,1,I,,20180427,20180510,20180510,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2018LAN000681",LANNETT,"CROSS HM, CHETTY S, ASUKILE MT, HUSSEY HS, LEE PAN EB, TUCKER LM. A PROPOSED MANAGEMENT ALGORITHM FOR LATE-ONSET EFAVIRENZ NEUROTOXICITY. S-AFR-MED-J. 2018;108(4):271-274",,,,,Y,,,20180510,,MD,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,148748951,HO,,,,,,,,,148748951,1,Antibiotic prophylaxis
14874964,148749641,1,I,,20180426,20180510,20180510,EXP,,FR-AUROBINDO-AUR-APL-2018-025008,AUROBINDO,,54,YR,,M,Y,,,20180510,,OT,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Nephropathy toxic;Renal tubular dysfunction,148749641,OT,,,,,,,,,148749641,1,Antiretroviral therapy
14879701,148797011,1,I,,20180507,20180511,20180511,EXP,,IE-ORION CORPORATION ORION PHARMA-18_00003603,ORION,"BRODERICK C,QUINLAN C. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;76(6):AB216.",37,YR,,F,Y,,,20180511,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Leukopenia;Product use in unapproved indication;Skin atrophy,148797011,OT,,,,,,,,,148797011,1,Sarcoidosis
14881427,148814271,1,I,,20130103,20180511,20180511,PER,,US-009507513-1805USA003216,MERCK,,20,YR,,F,Y,,,20180511,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,,,
14881855,148818551,1,I,,20130103,20180511,20180511,PER,,US-009507513-1805USA003795,MERCK,,30,YR,,F,Y,,,20180511,,CN,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Maternal exposure during pregnancy,,,,,,,,,,,148818551,1,Antiretroviral therapy
14884665,148846652,2,F,,20180511,20180511,20180522,EXP,,BR-MYLANLABS-2018M1030976,MYLAN,,,,,F,Y,,,20180519,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,148846652,CA,,,148846652,1,20171030,20180301,,,148846652,1,HIV infection
14890485,148904851,1,I,,20180503,20180514,20180514,EXP,,PHHY2018ZW002755,SANDOZ,"GUPTA A, MONTEPIEDRA G, AARON L, THERON G, MCCARTHY K, ONYANGO-MAKUMBI C ET AL.. RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY. TOPICS IN ANTIVIRAL MEDICINE. 2016;26:PP 60S",34,YR,,F,Y,,,20180514,,OT,ZW,ZW,EFAVIRENZ.,Hepatitis fulminant;Maternal exposure during pregnancy,148904851,DE,,,,,,,,,148904851,1,Antibiotic prophylaxis
14890489,148904891,1,I,,20180503,20180514,20180514,EXP,,PHHY2018TZ002761,SANDOZ,"GUPTA A, MONTEPIEDRA G, AARON L, THERON G, STERLING T, MCCARTHY K ET AL.. RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY.. TOPICS IN ANTIVIRAL MEDICINE. 2018;26:60S",35,YR,,F,Y,,,20180514,,OT,TZ,TZ,EFAVIRENZ.,Hepatitis fulminant;Hepatotoxicity,148904891,DE,,,,,,,,,148904891,1,Prophylaxis
14894899,148948991,1,I,,20180430,20180515,20180515,EXP,,JP-ACCORD-066928,ACCORD,"KOIZUMI Y, IMADOME KI, OTA Y, MINAMIGUCHI H, KODAMA Y, WATANABE D, ET AL. DUAL THREAT OF EPSTEIN-BARR VIRUS: AN AUTOPSY CASE REPORT OF HIV-POSITIVE PLASMABLASTIC LYMPHOMA COMPLICATING EBV-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. J CLIN IMMUNOL. 2018 APR 23",53,YR,,M,Y,,,20180515,,OT,JP,JP,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacteraemia;Bladder disorder;Bone marrow failure;CD4 lymphocytes decreased;CD4/CD8 ratio decreased;CD8 lymphocytes decreased;Coronary artery embolism;Cystitis;Embolism;Epstein-Barr virus infection;Escherichia infection;Haemorrhage;Histiocytosis haematophagic;Interferon gamma level increased;Interleukin level increased;Interleukin-2 receptor increased;Liver disorder;Lymph node fibrosis;Lymphadenopathy;Multiple organ dysfunction syndrome;Necrosis;Pulmonary embolism;Renal embolism;Septic shock;Serum ferritin increased;Splenic embolism;Systemic mycosis;Thyroid disorder;Urosepsis,148948991,OT,,,,,,,,,148948991,1,Plasmablastic lymphoma
14895215,148952151,1,I,,20180501,20180515,20180515,EXP,GB-FERRINGPH-2017FE05839,GB-ACCORD-066886,ACCORD,,,,,,Y,,,20180515,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,148952151,OT,,,,,,,,,148952151,1,Cardiovascular event prophylaxis
14897500,148975003,3,F,20171103,20180525,20180515,20180604,EXP,,ZA-GILEAD-2018-0338320,GILEAD,,0,YR,N,M,Y,3.81,KG,20180604,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,148975003,OT,,,148975003,1,20171103,20171108,,,148975003,1,HIV infection
14898979,148989791,1,I,,20180213,20180515,20180515,EXP,,PHHY2018FR025038,SANDOZ,,54,YR,,M,Y,,,20180516,,MD,FR,FR,EFAVIRENZ.,Drug ineffective;Haematotoxicity;Hepatitis C,148989791,OT,,,,,,,,,148989791,1,Acquired haemophilia
14900459,149004591,1,I,,20180502,20180516,20180516,EXP,,ZA-AUROBINDO-AUR-APL-2018-025512,AUROBINDO,,37,YR,,F,Y,,,20180516,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Confusional state;Encephalopathy;Gait disturbance,149004591,OT,,,,,,,,,149004591,1,HIV infection
14900505,149005052,2,F,2002,20180508,20180516,20180522,EXP,,PT-AUROBINDO-AUR-APL-2018-025856,AUROBINDO,,55,YR,,M,Y,,,20180522,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Drug ineffective;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,149005052,DE,,,149005052,1,1997,2010,,,149005052,1,HIV infection
14905487,149054871,1,I,,20170608,20180517,20180517,EXP,,UG-CIPLA LTD.-2017UG10688,CIPLA,,,,,,Y,,,20180517,,OT,GB,UG,EFAVIRENZ.,Death,149054871,OT,,,,,,,,,149054871,1,HIV infection
14906424,149064241,1,I,,20170608,20180517,20180517,EXP,,UG-CIPLA (EU) LIMITED-2017UG10619,CIPLA,,,,,,Y,,,20180517,,OT,GB,UG,EFAVIRENZ.,Pneumonia,149064241,DE,,,,,,,,,149064241,1,HIV infection
14907478,149074781,1,I,,20180502,20180517,20180517,EXP,,ZA-AUROBINDO-AUR-APL-2018-026564,AUROBINDO,,,,,F,Y,,,20180517,,OT,ZA,ZA,EFAVIRENZ.,Cerebellar ataxia;Encephalopathy;Gait disturbance,149074781,OT,,,,,,,,,149074781,1,HIV infection
14907874,149078742,2,F,,20180518,20180517,20180601,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17898,CIPLA,,,,,,Y,,,20180601,,OT,US,ZA,EFAVIRENZ.,Abnormal behaviour;Antiviral drug level above therapeutic;Petit mal epilepsy,149078742,OT,,,,,,,,,149078742,1,HIV infection
14909965,149099653,3,F,,20180528,20180517,20180529,EXP,,TR-GILEAD-2018-0338363,GILEAD,,,,A,,Y,,,20180529,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149099653,OT,,,,,,,,,149099653,1,HIV infection
14910087,149100873,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338916,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100873,OT,,,,,,,,,149100873,1,HIV infection
14910088,149100883,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338914,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100883,OT,,,,,,,,,149100883,1,HIV infection
14910089,149100893,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338915,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100893,OT,,,,,,,,,149100893,1,HIV infection
14910090,149100903,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338912,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100903,OT,,,,,,,,,149100903,1,HIV infection
14910091,149100913,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338913,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100913,OT,,,,,,,,,149100913,1,HIV infection
14910092,149100923,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338911,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149100923,OT,,,,,,,,,149100923,1,HIV infection
14910103,149101033,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338920,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101033,OT,,,,,,,,,149101033,1,HIV infection
14910104,149101043,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338919,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101043,OT,,,,,,,,,149101043,1,HIV infection
14910105,149101053,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338922,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101053,OT,,,,,,,,,149101053,1,HIV infection
14910106,149101063,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338921,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101063,OT,,,,,,,,,149101063,1,HIV infection
14910107,149101073,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338917,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101073,OT,,,,,,,,,149101073,1,HIV infection
14910108,149101083,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338918,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101083,OT,,,,,,,,,149101083,1,HIV infection
14910118,149101183,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338926,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101183,OT,,,,,,,,,149101183,1,HIV infection
14910120,149101203,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338925,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101203,OT,,,,,,,,,149101203,1,HIV infection
14910122,149101223,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338923,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101223,OT,,,,,,,,,149101223,1,HIV infection
14910123,149101233,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338924,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101233,OT,,,,,,,,,149101233,1,HIV infection
14910124,149101243,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338928,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101243,OT,,,,,,,,,149101243,1,HIV infection
14910125,149101253,3,F,,20180528,20180517,20180530,EXP,,TR-GILEAD-2018-0338927,GILEAD,,,,A,,Y,,,20180530,,MD,TR,TR,EFAVIRENZ.,Osteoporosis,149101253,OT,,,,,,,,,149101253,1,HIV infection
14911120,149111201,1,I,,20180504,20180518,20180518,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17892,CIPLA,,,,,,Y,,,20180518,,OT,US,ZA,EFAVIRENZ.,Abdominal pain upper;Antisocial behaviour;Nervous system disorder;Toxicity to various agents;Vomiting,149111201,OT,,,,,,,,,149111201,1,Perinatal HIV infection
14911344,149113442,2,F,,20180518,20180518,20180531,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17895,CIPLA,,,,,,Y,,,20180531,,OT,US,ZA,EFAVIRENZ.,Antiviral drug level above therapeutic;Generalised tonic-clonic seizure;Postictal state;Urinary incontinence,149113442,OT,,,,,,,,,149113442,1,Perinatal HIV infection
14911468,149114682,2,F,,20180518,20180518,20180601,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17889,CIPLA,,,,,,Y,,,20180601,,OT,US,ZA,EFAVIRENZ.,Aggression;Antiviral drug level above therapeutic;Generalised tonic-clonic seizure;Pyrexia,149114682,HO,,,,,,,,,149114682,1,Perinatal HIV infection
14915819,149158191,1,I,,20180514,20180518,20180518,EXP,,US-GILEAD-2018-0339050,GILEAD,"SHARMA, AV. DRUG-DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. 2018 ANNUAL MEETING OF THE AMERICAN GERIATRICS SOCIETY (AGS). 2018;UNK:1",73,YR,E,M,Y,,,20180518,,MD,US,US,EFAVIRENZ.,Drug interaction;Fanconi syndrome acquired,149158191,OT,,,,,,,,,149158191,1,Hepatitis C
14916965,149169652,2,F,201801,20180511,20180520,20180520,EXP,,PHHY2018ZA002551,NOVARTIS,,,,,F,Y,,,20180521,,CN,JP,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Retroviral rebound syndrome,149169652,OT,,,149169652,3,,20171204,,,149169652,1,Tuberculosis
14917098,149170981,1,I,,20180508,20180520,20180520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-042541,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180520,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,149170981,OT,,,,,,,,,149170981,1,Product used for unknown indication
14917168,149171681,1,I,,20180508,20180521,20180521,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043137,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20180521,,OT,PT,PT,SUSTIVA,Drug ineffective;Multiple organ dysfunction syndrome;Septic shock,149171681,DE,,,,,,,,,149171681,1,HIV infection
14920196,149201961,1,I,,20180514,20180521,20180521,EXP,,US-GILEAD-2018-0339129,GILEAD,,52,YR,A,M,Y,,,20180521,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Osteoporosis;Viral load increased,149201961,OT,,,,,,,,,149201961,1,HIV infection
14920891,149208911,1,I,,20171113,20180521,20180521,EXP,,ET-GILEAD-2017-0306152,GILEAD,"ANGAMO MT, CURTAIN CM, CHALMERS L, YILMA D, BEREZNICKI L. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2018;UNK:UNK, DOI: 10.1111/JCPT.12702",,,A,,Y,,,20180521,,OT,AU,ET,EFAVIRENZ.,Acute kidney injury,149208911,OT,,,,,,,,,149208911,1,Product used for unknown indication
14921347,149213473,3,F,20180413,20180615,20180522,20180626,EXP,,BR-HETERO CORPORATE-HET2018BR00424,HETERO,,1,MON,,F,Y,,,20180626,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,149213473,CA,,,149213473,1,20171030,20180301,,,149213473,1,HIV infection
14923461,149234611,1,I,,20180508,20180522,20180522,EXP,,TN-ALEMBIC PHARMACUETICALS LIMITED-2018SCAL000357,ALEMBIC,"FAKHFAKH N, ABDELMLAK R, AISSA S, KALLEL A, BOUDAWARA Y, BEL HADJ S. DISSEMINATED HISTOPLASMOSIS DIAGNOSED IN THE BONE MARROW OF AN HIV-INFECTED PATIENT: FIRST CASE IMPORTED IN TUNISIA. JOURNAL DE MYCOLOGIE MEDICALE. 2018;28 (1):211-214",,,,,Y,,,20180522,,OT,TN,TN,EFAVIRENZ.,Drug interaction;Treatment failure,149234611,DE,,,,,,,,,149234611,1,Histoplasmosis disseminated
14924110,149241101,1,I,,20180507,20180522,20180522,EXP,,FR-SEBELA IRELAND LIMITED-2018SEB00131,SEBELA,"LE MEUR L, TANTET C, LE MP, ET AL.. SERIOUS NEUROPSYCHIATRIC ADVERSE EFFECTS RELATED TO INTERACTION BETWEEN ITRACONAZOLE AND DARUNAVIR/RITONAVIR IN AN HIV-INFECTED PATIENT WITH CEREBRAL HISTOPLASMOSIS. J ANTIMICROB CHEMOTHER (DOI: 10.1093/JAC/DKX495). 2018;73(4):1108-1110",,,A,M,Y,,,20180522,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FURAMATE,Confusional state;Potentiating drug interaction,149241101,OT,,,149241101,4,2011,,,,149241101,1,Meningitis histoplasma
14926507,149265071,1,I,,20180508,20180523,20180523,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2018-03316,ALKEM,"ANGAMO MT, CHALMERS L, CURTAIN CM, YILMA D, ET AL.. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS.. 2018;1-9",,,,,Y,,,20180523,,OT,AU,AU,EFAVIRENZ.,Drug interaction;Hepatotoxicity,149265071,DE,,,,,,,,,149265071,1,Product used for unknown indication
14926508,149265081,1,I,,20180508,20180523,20180523,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2018-03258,ALKEM,"ANGAMO MT, CHALMERS L, CURTAIN CM, YILMA D, ET AL.. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS.. 2018;1-9",,,,,Y,,,20180523,,OT,AU,AU,EFAVIRENZ.,Drug interaction;Hepatotoxicity,149265081,HO,,,,,,,,,149265081,1,Product used for unknown indication
14927739,149277391,1,I,2009,20170403,20180523,20180523,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-028877,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20180523,,CN,GB,GB,SUSTIVA,Gynaecomastia,149277391,OT,,,149277391,1,2007,2010,,,149277391,1,HIV infection
14930245,149302451,1,I,,20180514,20180523,20180523,EXP,,TN-BAUSCH-BL-2018-014378,BAUSCH AND LOMB,"FAKHFAKH N, ABDELMLAK R, AISSA S, KALLEL A, BOUDAWARA Y, BEL HADJ S. DISSEMINATED HISTOPLASMOSIS DIAGNOSED IN THE BONE MARROW OF AN HIV-INFECTED PATIENT: FIRST CASE IMPORTED IN TUNISIA. JOURNAL DE MYCOLOGIE MEDICALE. 2018;28(1):211-214.",34,YR,,F,Y,,,20180523,,MD,TN,TN,EFAVIRENZ.,Cytomegalovirus infection;Hypoxia;Pneumonia cytomegaloviral,149302451,OT,,,,,,,,,149302451,1,Cerebral toxoplasmosis
14931261,149312611,1,I,,20180518,20180524,20180524,EXP,,CA-ROCHE-2126762,ROCHE,,52,YR,,M,Y,,,20180524,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,149312611,OT,,,,,,,,,149312611,1,HIV infection
14931694,149316942,2,F,,20180529,20180524,20180611,EXP,,GB-AUROBINDO-AUR-APL-2018-027240,AUROBINDO,,,,,F,Y,,,20180611,,OT,GB,GB,Efavirenz Film-coated Tablet,Breast feeding;Hypertension;Liver function test increased;Maternal exposure during pregnancy;Product use issue;Stillbirth,149316942,OT,,,,,,,,,149316942,1,HIV infection
14933609,149336091,1,I,201803,20180510,20180524,20180524,EXP,,GB-AUROBINDO-AUR-APL-2018-027101,AUROBINDO,,,,,M,Y,,,20180524,,MD,GB,GB,EFAVIRENZ.,Blood HIV RNA increased;Drug interaction,149336091,OT,,,,,,,,,149336091,1,Product used for unknown indication
14933630,149336301,1,I,,20180510,20180524,20180524,EXP,,GB-AUROBINDO-AUR-APL-2018-027236,AUROBINDO,,,,I,,Y,,,20180524,,OT,GB,GB,Efavirenz Film-coated Tablet,Exposure via breast milk;Foetal exposure during pregnancy;Polydactyly,149336301,OT,,,,,,,,,149336301,1,Product used for unknown indication
14936059,149360591,1,I,20170908,20180516,20180524,20180524,EXP,,ZA-GILEAD-2018-0339854,GILEAD,,,,,F,Y,,,20180524,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery,149360591,OT,,,149360591,1,20170908,20171105,,,149360591,1,HIV infection
14936120,149361201,1,I,,20171113,20180524,20180524,EXP,,ET-GILEAD-2017-0305634,GILEAD,"ANGAMO MT, CURTAIN CM, CHALMERS L, YILMA D, BEREZNICKI L. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2018;UNK:UNK, DOI: 10.1111/JCPT.12702",,,A,,Y,,,20180524,,OT,AU,ET,EFAVIRENZ.,Acute kidney injury,149361201,OT,,,,,,,,,149361201,1,Product used for unknown indication
14936127,149361271,1,I,20170908,20180516,20180524,20180524,EXP,,ZA-GILEAD-2018-0339857,GILEAD,,,,N,F,Y,,,20180524,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Neonatal respiratory distress,149361271,OT,,,149361271,1,20170908,20171105,,,149361271,1,HIV infection
14937462,149374621,1,I,,20180510,20180525,20180525,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043920,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180525,,OT,ZA,GB,EFAVIRENZ.,Gestational hypertension;Live birth;Maternal exposure during pregnancy;Product use issue,149374621,OT,,,,,,,,,149374621,1,HIV infection
14937867,149378671,1,I,,20180510,20180525,20180525,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043783,BRISTOL MYERS SQUIBB,,,,I,,Y,,,20180525,,OT,GB,GB,EFAVIRENZ.,Exposure via breast milk;Foetal exposure during pregnancy;Polydactyly,149378671,CA,,,,,,,,,149378671,1,Product used for unknown indication
14940410,149404101,1,I,,20180514,20180525,20180525,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-045054,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20180525,,OT,TN,TN,EFAVIRENZ.,Cytomegalovirus infection;Histoplasmosis disseminated;Hypoxia;Labelled drug-drug interaction medication error;Pneumonia cytomegaloviral;Treatment failure,149404101,LT,,,,,,,,,149404101,1,HIV infection
14940798,149407982,2,F,,20180521,20180525,20180604,EXP,,ZA-MYLANLABS-2018M1033998,MYLAN,,0,YR,,F,Y,1.67,KG,20180604,,CN,ZA,ZA,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydrocephalus;Maternal drugs affecting foetus;Premature baby,149407982,OT,,,149407982,1,20170908,20171105,,,149407982,1,Product used for unknown indication
14942174,149421741,1,I,,20180514,20180528,20180528,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-048844,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180528,,OT,AU,ET,EFAVIRENZ.,Hepatotoxicity,149421741,OT,,,,,,,,,149421741,1,Product used for unknown indication
14942665,149426651,1,I,,20180514,20180528,20180528,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-046512,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180528,,OT,AU,ET,EFAVIRENZ.,Drug interaction;Hepatotoxicity,149426651,OT,,,,,,,,,149426651,1,Product used for unknown indication
14942766,149427661,1,I,,20180515,20180528,20180528,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-048195,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180528,,OT,ZA,GB,EFAVIRENZ.,Liver function test increased;Maternal exposure during pregnancy;Product use issue;Stillbirth,149427661,OT,,,,,,,,,149427661,1,HIV infection
14942774,149427741,1,I,,20180515,20180528,20180528,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-048203,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180528,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Umbilical cord around neck,149427741,OT,,,,,,,,,149427741,1,Product used for unknown indication
14944205,149442051,1,I,,20180524,20180528,20180528,EXP,,PHHY2014DE185077,SANDOZ,"PETERSEN J, HERZER K, FERENCI P, GSCHWANTLER M, CORNBERG M, INGILIZ P ET AL. JIMENEZ-EXPOSITO M AND ZEUZEM S. DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH ADVANCED LIVER DISEASE: RESULTS OF A EUROPEAN COMPASSIONATE USE PROGRAM. JOURNAL OF HEPATOLOGY. 2016;64 (2S1):S825",,,,,Y,,,20180529,,,COUNTRY NOT SPECIFIED,DE,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,149442051,DE,,,,,,,,,149442051,1,Chronic hepatitis C
14944275,149442751,1,I,20180217,20180517,20180528,20180528,EXP,,PHHY2018LS005904,NOVARTIS,,42,YR,,F,Y,70,KG,20180529,,CN,LS,LS,EFAVIRENZ.,Confusional state;Speech disorder;Substance-induced psychotic disorder,149442751,HO,,,149442751,1,20180215,20180218,,,149442751,1,Tuberculosis
14945535,149455351,1,I,,20180315,20180529,20180529,EXP,,TN-ACCORD-067396,ACCORD,"FAKHFAKH N, ABDELMLAK R, AISSA S, KALLEL A, BOUDAWARA Y, BEL HADJ S ET AL. DISSEMINATED HISTOPLASMOSIS DIAGNOSED IN THE BONE MARROW OF AN HIV-INFECTED PATIENT: FIRST CASE IMPORTED IN TUNISIA. JOURNAL DE MYCOLOGIE MEDICALE. 2018; 28(1): 211-214. DOI: HTTPS://DOI.ORG/10.1016/J.MYCMED.2018.02.008",34,YR,,F,Y,,,20180529,,OT,TN,TN,EFAVIRENZ.,Drug interaction;Treatment failure,149455351,HO,,,,,,,,,149455351,1,Histoplasmosis disseminated
14950570,149505701,1,I,2015,20180528,20180530,20180530,EXP,FR-AFSSAPS-LM20180416,FR-ABBVIE-18S-056-2369897-00,ABBVIE,,,,,M,Y,105,KG,20180530,,MD,FR,FR,SUSTIVA,Condition aggravated;Hepatitis,149505701,HO,,,149505701,1,2005,,,,149505701,1,HIV infection
14953354,149533542,2,F,,20180523,20180530,20180531,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2018GSK094520,VIIV,"PORTILLA-JIMENEZ A, ARIAS-DELGADILLO C, PARRA-AVILA I, MARINO-VAZQUEZ L, ROSADO-CANTO R, MORALES-BUENROSTRO L.. LONG-TERM EVOLUTION OF TRANSPLANT RECIPIENTS^ KIDNEY WITH HIV INFECTION.. REVISTA MEXICANA DE TRASPLANTES. 2017;6 (1):66",53,YR,,M,Y,,,20180531,,MD,MX,MX,EFAVIRENZ.,Diabetes mellitus;Transplant rejection,149533542,OT,,,,,,,,,149533542,1,HIV infection
14953361,149533612,2,F,,20180523,20180530,20180531,EXP,,MX-GLAXOSMITHKLINE-MX2018GSK094520,GLAXOSMITHKLINE,"PORTILLA-JIMENEZ A, ARIAS-DELGADILLO C, PARRA-AVILA I, MARINO-VAZQUEZ L, ROSADO-CANTO R, MORALES-BUENROSTRO L.. LONG-TERM EVOLUTION OF TRANSPLANT RECIPIENTS^ KIDNEY WITH HIV INFECTION.. REVISTA MEXICANA DE TRASPLANTES. 2017;6 (1):66",53,YR,,M,Y,,,20180531,,MD,MX,MX,EFAVIRENZ.,Diabetes mellitus;Transplant rejection,149533612,OT,,,,,,,,,149533612,1,HIV infection
14957287,149572871,1,I,,20180520,20180531,20180531,EXP,,CA-APOTEX-2018AP014010,APOTEX,,46,YR,,M,Y,,,20180531,,CN,CA,CA,EFAVIRENZ.,Drug interaction;Transaminases increased,149572871,OT,,,,,,,,,149572871,1,Pulmonary tuberculosis
14959465,149594651,1,I,,20180522,20180531,20180531,EXP,,GB-MYLANLABS-2018M1034971,MYLAN,,66,YR,,M,Y,,,20180524,,PH,GB,GB,EFAVIRENZ.,Death,149594651,DE,,,,,,,,,149594651,1,HIV infection
14959722,149597222,2,F,,20180519,20180531,20180601,EXP,,ZA-AUROBINDO-AUR-APL-2014-04025,AUROBINDO,,34,YR,,M,Y,,,20180602,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Virologic failure,149597222,OT,,,,,,,,,149597222,1,Antiretroviral therapy
14961417,149614171,1,I,,20180517,20180601,20180601,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2018013928,MACLEODS,,,,,,Y,,,20180601,,CN,FR,FR,EFAVIRENZ.,Fanconi syndrome;Nephropathy toxic;Renal tubular dysfunction,149614171,OT,,,,,,,,,149614171,1,Antiretroviral therapy
14961911,149619111,1,I,,20180503,20180601,20180601,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17786,CIPLA,,,,,,Y,,,20180601,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619111,OT,,,,,,,,,149619111,1,HIV infection WHO clinical stage IV
14962390,149623901,1,I,,20171204,20180601,20180601,EXP,,ET-AUROBINDO-AUR-APL-2017-46000,AUROBINDO,,30,YR,,M,Y,,,20180601,,OT,DE,ET,EFAVIRENZ.,Gene mutation;Pathogen resistance;Virologic failure,149623901,OT,,,,,,,,,149623901,1,Antiretroviral therapy
14963407,149634071,1,I,,20180521,20180601,20180601,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-049478,BRISTOL MYERS SQUIBB,,47,YR,,M,Y,,,20180601,,OT,TW,TW,EFAVIRENZ.,Non-cirrhotic portal hypertension,149634071,OT,,,,,,,,,149634071,1,HIV infection
14963482,149634821,1,I,20180503,20180524,20180601,20180601,EXP,,PHHY2018MM011631,NOVARTIS,,54,YR,,M,Y,41,KG,20180601,,CN,MM,MM,EFAVIRENZ.,Aggression;Agitation;Depression;Injection site vasculitis;Suicidal ideation,149634821,OT,,,149634821,1,20180217,20180503,,,149634821,1,Product used for unknown indication
14964933,149649331,1,I,,20180523,20180601,20180601,EXP,,TW-MYLANLABS-2018M1036498,MYLAN,"HO Y-H, YI LW, HSU Y-H, WANG L-S. NON-CIRRHOTIC PORTAL HYPERTENSION IN HIV PATIENTS. INT-J-ANTIMICROB-AGENTS 2017;50 (SUPPL. 2):S199.",47,YR,,M,Y,,,20180601,,OT,TW,TW,EFAVIRENZ.,Gastric ulcer;Non-cirrhotic portal hypertension;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,149649331,HO,,,,,,,,,149649331,1,HIV infection
14968323,149683231,1,I,,20180522,20180604,20180604,EXP,GB-MHRA-EYC 00171779,GB-LUPIN PHARMACEUTICALS INC.-2018-04098,LUPIN,,47,YR,,F,Y,109,KG,20180604,,CN,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,149683231,HO,,,149683231,1,20170418,20171215,,,149683231,1,HIV infection
14968758,149687581,1,I,,,20180511,20180511,DIR,,,FDA-CTU,,53,YR,,F,N,,,20180511,N,OT,US,US,EFAVIRENZ.,Nausea;Weight decreased,149687581,OT,149687581,HP,149687581,1,,,8,YR,149687581,1,HIV infection
14975368,149753682,2,F,2018,20180613,20180605,20180620,EXP,,MM-009507513-1805MMR014056,MERCK,,54,YR,,M,Y,41,KG,20180620,,CN,JP,MM,EFAVIRENZ.;efavirenz (+) lamivudine (+) tenofovir disoproxil fumarate,Aggression;Agitated depression;Dehydration;Diarrhoea;Dizziness postural;Dyspnoea exertional;Haemorrhoids;Injection site pain;Injection site vasculitis;Mucous stools;Suicidal ideation;Vomiting,149753682,HO,,,149753682,1,20180217,20180503,,,149753682,1,Product used for unknown indication
14976004,149760042,2,F,,20180528,20180605,20180625,EXP,,FR-MYLANLABS-2018M1037134,MYLAN,,44,YR,,F,Y,,,20180625,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,149760042,OT,,,149760042,1,199902,,,,149760042,1,HIV infection
14981967,149819671,1,I,,20180525,20180607,20180607,EXP,,US-CIPLA LTD.-2018US18954,CIPLA,,,,,,Y,,,20180607,,OT,US,US,EFAVIRENZ.,Acute kidney injury,149819671,OT,,,,,,,,,149819671,1,HIV infection
14982778,149827782,2,F,2016,20180604,20180607,20180607,EXP,,PHHY2018MM016118,NOVARTIS,,53,YR,,F,Y,,,20180607,,CN,US,MM,EFAVIRENZ.,"Bone tuberculosis;Burning sensation;Decubitus ulcer;Deep vein thrombosis;Hallucination, visual;Hyperaesthesia;Hypotension;Insomnia;Muscle twitching;Necrotising fasciitis;Oedema;Psychotic disorder;Psychotic symptom;Pulmonary embolism;Septic shock",149827782,DS,,,149827782,1,20160609,20161214,,,149827782,1,Tuberculosis
14983919,149839191,1,I,,20180531,20180607,20180607,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018GSK100503,VIIV,,48,YR,,F,Y,,,20180607,,MD,FR,FR,SUSTIVA,Drug interaction;Tuberculosis,149839191,OT,,,149839191,1,20160528,20160704,,,149839191,1,HIV infection
14984254,149842541,1,I,,20180531,20180607,20180607,EXP,,ZA-VIIV HEALTHCARE LIMITED-GB2018097202,VIIV,,,,,F,Y,,,20180607,,OT,ZA,GB,EFAVIRENZ.,Exposure during pregnancy;Liver function test increased;Product use issue;Stillbirth,149842541,OT,,,,,,,,,149842541,1,HIV infection
14986565,149865651,1,I,2015,20180528,20180608,20180608,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-049452,BRISTOL MYERS SQUIBB,,,,,M,Y,105,KG,20180608,,MD,FR,FR,SUSTIVA,Condition aggravated;Hepatitis,149865651,OT,,,149865651,1,2005,,,,149865651,1,HIV infection
14986717,149867171,1,I,201804,20180528,20180608,20180608,EXP,,FR-BIOVERATIV-2018BV000329,BIOVERATIV,,,,,M,Y,105,KG,20180607,,MD,FR,FR,SUSTIVA,Hepatitis,149867171,HO,,,149867171,1,201802,,,,149867171,1,Factor VIII deficiency
14992184,149921842,2,F,,20180625,20180608,20180629,EXP,,GH-GILEAD-2018-0343047,GILEAD,"BADII VS, BUABENG KO, POKU TA, FORKUO AD, BOAMAH BB, ARHIN SM, KPEWOU DE.. TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IS ASSOCIATED WITH SUPERIOR CD4 T CELLS REPOPULATION COMPARED TO ZIDOVUDINE-BASED HAART IN HIV 1 INFECTED ADULTS. INTERNATIONAL JOURNAL OF CHRONIC DISEASE PRINT. 2018;UNK:8 DOI.ORG/10.1155/2018/3702740",,,A,F,Y,38,KG,20180629,,MD,GH,GH,EFAVIRENZ.,Nephropathy,149921842,DE,,,149921842,2,20160705,,,,149921842,1,HIV infection
14994542,149945423,3,F,,20180626,20180611,20180630,PER,,BR-HETERO CORPORATE-HET2018BR00512,HETERO,,,,,F,Y,2.25,KG,20180630,,OT,BR,BR,EFAVIRENZ+LAMIVUDINE+TENOFOVIR DISOPROXIL FUM,Acrochordon;Foetal exposure during pregnancy,,,,,149945423,1,20171128,20180504,,,149945423,1,HIV infection
14997996,149979961,1,I,201804,20180528,20180611,20180611,EXP,,FR-BIOVITRUM-2018BV000329,BIOVITRUM,,,,,M,Y,105,KG,20180606,,MD,FR,FR,SUSTIVA,Hepatitis,149979961,HO,,,149979961,1,201802,,,,149979961,1,Factor VIII deficiency
14998093,149980931,1,I,,20180529,20180611,20180611,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-053800,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20180611,,MD,GB,GB,EFAVIRENZ.,Burkitt's lymphoma;Pancytopenia,149980931,HO,,,,,,,,,149980931,1,HIV infection
15000172,150001722,2,F,2017,20180620,20180612,20180622,EXP,,CO-AUROBINDO-AUR-APL-2018-031555,AUROBINDO,,39,YR,,M,Y,68.3,KG,20180622,,PH,CO,CO,EFAVIRENZ.,Treatment failure;Viral load increased,150001722,OT,,,150001722,1,201607,,,,150001722,1,HIV infection
15000333,150003331,1,I,,20180606,20180612,20180612,PER,,US-VIIV HEALTHCARE LIMITED-US2018GSK101999,VIIV,,,,,F,Y,,,20180612,,CN,US,US,SUSTIVA,Weight increased,,,,,,,,,,,150003331,1,Product used for unknown indication
15003212,150032121,1,I,,20180606,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001947",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO A, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37:.",17,YR,,F,Y,,,20180613,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150032121,OT,,,,,,,,,150032121,1,HIV infection
15003485,150034851,1,I,,20180606,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001948",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO A, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):.",16,YR,,M,Y,,,20180613,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150034851,OT,,,,,,,,,150034851,1,HIV infection
15003986,150039861,1,I,,20180606,20180613,20180613,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001944",BOEHRINGER INGELHEIM,"BRUZZESE E, VECCHIO, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37:.",18,YR,,F,Y,,,20180613,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150039861,OT,,,,,,,,,150039861,1,HIV infection
15007233,150072331,1,I,20180524,20180608,20180613,20180613,EXP,,LS-JNJFOC-20180612361,JANSSEN,,32,YR,A,F,Y,35,KG,20180613,,MD,LS,LS,EFAVIRENZ.,Abdominal pain upper;Asthenia;Blood alkaline phosphatase increased;Dizziness;Dysuria;Gamma-glutamyltransferase increased;Vomiting,150072331,OT,,,150072331,1,20180311,20180606,,,150072331,1,Tuberculosis
15007684,150076841,1,I,20170618,20180601,20180613,20180613,EXP,SE-MPA-2018-001593,SE-MYLANLABS-2018M1038820,MYLAN,,32,YR,,F,Y,,,20180608,,MD,SE,SE,EFAVIRENZ.,Dizziness,150076841,OT,,,,,,,,,150076841,1,HIV infection
15009609,150096091,1,I,,20180531,20180614,20180614,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-050860,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20180614,,MD,GB,GB,EFAVIRENZ.,Toxicity to various agents,150096091,DE,,,,,,,,,150096091,1,HIV infection
15011880,150118801,1,I,,20180608,20180614,20180614,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2018102598,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37,16,YR,,M,Y,,,20180614,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150118801,OT,,,,,,,,,150118801,1,HIV infection
15011882,150118821,1,I,,20180608,20180614,20180614,EXP,,IT-GLAXOSMITHKLINE-IT2018102598,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44:37,16,YR,,M,Y,,,20180614,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150118821,OT,,,,,,,,,150118821,1,HIV infection
15012239,150122393,3,F,,20180615,20180614,20180627,EXP,,BR-MYLANLABS-2018M1039517,MYLAN,,,,,F,Y,,,20180627,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Foetal exposure during pregnancy;Genital prolapse;Vaginal cyst,150122393,CA,,,150122393,1,20171128,20171127,,,150122393,1,Product used for unknown indication
15012916,150129161,1,I,,20180604,20180614,20180614,PER,,US-TEVA-2018-US-905535,TEVA,SHARMA AV. DRUG-DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J-AM-GERIATR-SOC 2018;66 (SUPPL. 2):S17.,73,YR,,M,Y,,,20180614,,OT,US,US,EFAVIRENZ.,Drug interaction;Fanconi syndrome,150129161,OT,,,,,,,,,150129161,1,HIV infection
15013095,150130951,1,I,,20180604,20180614,20180614,EXP,,PT-GILEAD-2018-0343029,GILEAD,"LOUREIRO RV, COSTA MN, GERMANO I, CALINAS F. PSEUDORESISTANCE OF HEPATITIS B VIRUS TO TENOFOVIR WITH EMTRICITABINE. AIDS. 2018;32(10):1387-1388",52,YR,A,M,Y,,,20180614,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Drug ineffective for unapproved indication;Drug interaction;Genotype drug resistance test positive,150130951,OT,,,150130951,1,201206,,,,150130951,1,HIV infection
15013293,150132931,1,I,,20180606,20180614,20180614,EXP,,US-GILEAD-2018-0344297,GILEAD,,51,YR,A,M,Y,,,20180614,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alcoholism;Back pain;Blood cholesterol increased;Depression;Disturbance in attention;Hypertension;Memory impairment;Product use issue,150132931,OT,,,,,,,,,150132931,1,Product used for unknown indication
15014930,150149301,1,I,,20180604,20180615,20180615,EXP,,US-AUROBINDO-AUR-APL-2018-031267,AUROBINDO,"SHARMA AV.. LEDIPASVIR/SOFOSBUVIR/TENOFOVIR DISOPROXIL-FUMARATE INTERACTION, FANCONI SYNDROME: CASE REPORT. REACTIONS WEEKLY. 2018;1704:P219",73,YR,,M,Y,,,20180615,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome;Nausea;Vomiting,150149301,HO,,,,,,,,,150149301,1,HIV infection
15017062,150170621,1,I,20180405,20180607,20180615,20180615,EXP,,PHHY2018MM019390,NOVARTIS,,28,YR,,M,Y,38,KG,20180615,,CN,MM,MM,EFAVIRENZ.,Incorrect drug administration duration;Thrombocytopenia;Vision blurred,150170621,OT,,,150170621,1,20161227,201701,,,150170621,1,Tuberculosis
15019368,150193681,1,I,20180501,20180607,20180617,20180617,EXP,,PHHY2018LS018730,NOVARTIS,,48,YR,,M,Y,51,KG,20180617,,CN,LS,LS,EFAVIRENZ.,Deep vein thrombosis;Pain in extremity;Peripheral swelling,150193681,HO,,,150193681,2,20171220,,,,150193681,1,Tuberculosis
15019621,150196211,1,I,,20180607,20180618,20180618,EXP,,US-CIPLA LTD.-2018US19144,CIPLA,,,,,,Y,,,20180618,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Product substitution issue;Viral load increased,150196211,OT,,,,,,,,,150196211,1,Product used for unknown indication
15020020,150200201,1,I,,20180613,20180618,20180618,EXP,,GB-ABBVIE-18P-167-2388759-00,ABBVIE,,,,,M,Y,,,20180618,,CN,GB,GB,EFAVIRENZ.,Surgery,150200201,HO,,,150200201,1,20161215,,,,150200201,1,Product used for unknown indication
15020285,150202851,1,I,,20180605,20180618,20180618,EXP,,GB-AUROBINDO-AUR-APL-2018-031365,AUROBINDO,,,,A,,Y,,,20180618,,OT,GB,GB,EFAVIRENZ.,Psychotic disorder,150202851,OT,,,,,,,,,150202851,1,Perinatal HIV infection
15022546,150225461,1,I,,20180608,20180618,20180618,EXP,,IT-GLAXOSMITHKLINE-IT2018102596,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),18,YR,,F,Y,,,20180618,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225461,OT,,,,,,,,,150225461,1,HIV infection
15022547,150225471,1,I,,20180608,20180618,20180618,EXP,,IT-GLAXOSMITHKLINE-NG2018102597,GLAXOSMITHKLINE,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),17,YR,,F,Y,,,20180618,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225471,OT,,,,,,,,,150225471,1,HIV infection
15022569,150225691,1,I,,20180608,20180618,20180618,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2018102596,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),18,YR,,F,Y,,,20180618,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225691,OT,,,,,,,,,150225691,1,HIV infection
15022571,150225711,1,I,,20180608,20180618,20180618,EXP,,IT-VIIV HEALTHCARE LIMITED-NG2018102597,VIIV,TAMBARO O. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37),17,YR,,F,Y,,,20180618,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150225711,OT,,,,,,,,,150225711,1,HIV infection
15027468,150274681,1,I,,20180606,20180619,20180619,EXP,,IT-AUROBINDO-AUR-APL-2018-031662,AUROBINDO,,16,YR,,M,Y,,,20180619,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150274681,OT,,,,,,,,,150274681,1,HIV infection
15027477,150274771,1,I,,20180606,20180619,20180619,EXP,,IT-AUROBINDO-AUR-APL-2018-031687,AUROBINDO,,17,YR,,F,Y,,,20180619,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150274771,OT,,,,,,,,,150274771,1,HIV infection
15027629,150276291,1,I,,20180606,20180619,20180619,EXP,,IT-AUROBINDO-AUR-APL-2018-031684,AUROBINDO,,18,YR,,F,Y,,,20180619,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150276291,OT,,,,,,,,,150276291,1,HIV infection
15037386,150373861,1,I,,20170522,20180620,20180620,EXP,,US-GILEAD-2017-0274853,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373861,OT,,,,,,,,,150373861,1,HIV infection
15037387,150373871,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345022,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373871,OT,,,,,,,,,150373871,1,HIV infection
15037391,150373911,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345431,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373911,OT,,,,,,,,,150373911,1,HIV infection
15037394,150373941,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345433,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150373941,OT,,,,,,,,,150373941,1,HIV infection
15037400,150374001,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345434,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374001,OT,,,,,,,,,150374001,1,HIV infection
15037401,150374011,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345432,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374011,OT,,,,,,,,,150374011,1,HIV infection
15037419,150374191,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345435,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374191,OT,,,,,,,,,150374191,1,HIV infection
15037422,150374221,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345436,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374221,OT,,,,,,,,,150374221,1,HIV infection
15037427,150374271,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345437,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374271,OT,,,,,,,,,150374271,1,HIV infection
15037428,150374281,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345438,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374281,OT,,,,,,,,,150374281,1,HIV infection
15037447,150374471,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345445,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374471,OT,,,,,,,,,150374471,1,HIV infection
15037451,150374511,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345444,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374511,OT,,,,,,,,,150374511,1,HIV infection
15037452,150374521,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345443,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374521,OT,,,,,,,,,150374521,1,HIV infection
15037473,150374731,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345439,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374731,OT,,,,,,,,,150374731,1,HIV infection
15037474,150374741,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345440,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374741,OT,,,,,,,,,150374741,1,HIV infection
15037487,150374871,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345441,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374871,OT,,,,,,,,,150374871,1,HIV infection
15037488,150374881,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345442,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374881,OT,,,,,,,,,150374881,1,HIV infection
15037495,150374951,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345446,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374951,OT,,,,,,,,,150374951,1,HIV infection
15037496,150374961,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345447,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150374961,OT,,,,,,,,,150374961,1,HIV infection
15037508,150375081,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345448,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375081,OT,,,,,,,,,150375081,1,HIV infection
15037554,150375541,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345449,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375541,OT,,,,,,,,,150375541,1,HIV infection
15037560,150375601,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345450,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375601,OT,,,,,,,,,150375601,1,HIV infection
15037588,150375881,1,I,20171227,20180607,20180620,20180620,EXP,,ZA-MYLANLABS-2018M1043162,MYLAN,,22,YR,,M,Y,42,KG,20180619,,MD,ZA,ZA,EFAVIRENZ.,Bundle branch block left;Chest pain;Electrocardiogram QT prolonged;Incorrect drug administration duration,150375881,LT,,,150375881,1,20170330,20171227,,,150375881,1,Pulmonary tuberculosis
15037589,150375891,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345451,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375891,OT,,,,,,,,,150375891,1,HIV infection
15037599,150375991,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345452,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150375991,OT,,,,,,,,,150375991,1,HIV infection
15037632,150376321,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345454,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376321,OT,,,,,,,,,150376321,1,HIV infection
15037653,150376531,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345453,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376531,OT,,,,,,,,,150376531,1,HIV infection
15037665,150376651,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345455,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376651,OT,,,,,,,,,150376651,1,HIV infection
15037667,150376671,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345456,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376671,OT,,,,,,,,,150376671,1,HIV infection
15037675,150376751,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345457,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376751,OT,,,,,,,,,150376751,1,HIV infection
15037676,150376761,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345458,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376761,OT,,,,,,,,,150376761,1,HIV infection
15037692,150376921,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345461,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376921,OT,,,,,,,,,150376921,1,HIV infection
15037695,150376951,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345460,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376951,OT,,,,,,,,,150376951,1,HIV infection
15037699,150376991,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345459,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150376991,OT,,,,,,,,,150376991,1,HIV infection
15037794,150377941,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345462,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150377941,OT,,,,,,,,,150377941,1,HIV infection
15037841,150378411,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345465,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378411,OT,,,,,,,,,150378411,1,HIV infection
15037845,150378451,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345463,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378451,OT,,,,,,,,,150378451,1,HIV infection
15037846,150378461,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345464,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378461,OT,,,,,,,,,150378461,1,HIV infection
15037860,150378601,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345466,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378601,OT,,,,,,,,,150378601,1,HIV infection
15037862,150378621,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345468,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378621,OT,,,,,,,,,150378621,1,HIV infection
15037863,150378631,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345469,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378631,OT,,,,,,,,,150378631,1,HIV infection
15037866,150378661,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345467,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378661,OT,,,,,,,,,150378661,1,HIV infection
15037869,150378691,1,I,,20180611,20180620,20180620,EXP,,US-GILEAD-2018-0345470,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180620,,OT,US,US,EFAVIRENZ.,Osteoporosis,150378691,OT,,,,,,,,,150378691,1,HIV infection
15043791,150437911,1,I,,20170522,20180621,20180621,EXP,,US-GILEAD-2017-0274374,GILEAD,"LAFLEUR J, BRESS A, MYER J, ROSENBLATT L, CROOK J, KNIPPENBERG K, NYMA H, BEDIMO R, TEBAS P AND ESKER S. TENOFOVIR-ASSOCIATED BONE ADVERSE OUTCOMES AMONG A US NATIONAL HISTORICAL COHORT OF HIV INFECTED VETERANS: RISK MODIFICATION BY CONCOMITANT ANTIRETROVIRALS. INFECTIOUS DISEASES AND THERAPY. 2018;7:293-308",,,A,,Y,,,20180621,,OT,US,US,EFAVIRENZ.,Osteoporosis,150437911,OT,,,,,,,,,150437911,1,HIV infection
15046619,150466191,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0346525,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466191,OT,,,,,,,,,150466191,1,HIV infection
15046628,150466281,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0346527,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466281,OT,,,,,,,,,150466281,1,HIV infection
15046631,150466311,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0346526,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466311,OT,,,,,,,,,150466311,1,HIV infection
15046648,150466481,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0346529,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466481,OT,,,,,,,,,150466481,1,HIV infection
15046649,150466491,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0346528,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466491,OT,,,,,,,,,150466491,1,HIV infection
15046740,150467401,1,I,,20180611,20180621,20180621,EXP,,IT-GILEAD-2018-0344332,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150467401,OT,,,,,,,,,150467401,1,HIV infection
15048350,150483501,1,I,,20180613,20180622,20180622,EXP,,IT-ROCHE-2141539,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):-.",17,YR,,F,Y,,,20180622,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,150483501,OT,,,,,,,,,150483501,1,HIV infection
15048355,150483551,1,I,,20180613,20180622,20180622,EXP,,IT-ROCHE-2141544,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITALIAN JOURNAL OF PEDIATRICS. 2018;44(37):-.",16,YR,,M,Y,,,20180622,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150483551,OT,,,,,,,,,150483551,1,HIV infection
15049066,150490661,1,I,20180317,20180618,20180622,20180622,EXP,,PHHY2018LS027107,NOVARTIS,,57,YR,,M,Y,47,KG,20180622,,CN,LS,LS,EFAVIRENZ.,Abdominal distension;Confusional state;General physical health deterioration;Infection;Pancytopenia;Progressive multifocal leukoencephalopathy;Renal injury;Respiratory failure;Strabismus;Vomiting,150490661,OT,,,150490661,1,20180317,20180323,,,150490661,1,Tuberculosis
15051465,150514651,1,I,20180610,20180614,20180622,20180622,EXP,,PHHO2018MW007348,NOVARTIS,,51,YR,,M,Y,,,20180622,,MD,MW,MW,EFAVIRENZ.,Sepsis,150514651,DE,,,150514651,1,20180606,20180610,,,150514651,1,Cryptosporidiosis infection
15052822,150528221,1,I,20171024,20180612,20180622,20180622,PER,,BY-BAYER-2018-112647,BAYER,,42,YR,A,M,Y,60,KG,20180622,,OT,BY,US,EFAVIRENZ.,Hypoacusis,150528221,DS,,,150528221,1,20170928,20171220,,,,,
15057866,150578661,1,I,20180530,20180604,20180625,20180625,EXP,,GP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-052113,BRISTOL MYERS SQUIBB,,49,YR,,F,Y,,,20180625,,OT,GP,FR,SUSTIVA,Attention deficit/hyperactivity disorder;Headache;Hypertension;Intracranial pressure increased;Vertigo,150578661,OT,,,150578661,1,19990820,,,,150578661,1,HIV infection
15058934,150589341,1,I,,20180621,20180625,20180625,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018111756,VIIV,"LOUREIRO RV, COSTA MN, GERMANO I, CALINAS F. PSEUDORESISTANCE OF HEPATITIS B VIRUS TO TENOFOVIR WITH EMTRICITABINE. AIDS. 2018;32(10):1387-1388. DOI: 10.1097/QAD.0000000000001835.",52,YR,,M,Y,,,20180625,,MD,PT,PT,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Infection,150589341,OT,,,,,,,,,150589341,1,HIV infection
15059175,150591751,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058319,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591751,OT,,,,,,,,,150591751,1,HIV infection
15059176,150591761,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058322,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591761,OT,,,,,,,,,150591761,1,HIV infection
15059177,150591771,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058321,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591771,OT,,,,,,,,,150591771,1,HIV infection
15059181,150591811,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058324,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591811,OT,,,,,,,,,150591811,1,HIV infection
15059182,150591821,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058326,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591821,OT,,,,,,,,,150591821,1,HIV infection
15059183,150591831,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058320,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591831,OT,,,,,,,,,150591831,1,HIV infection
15059186,150591861,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058325,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591861,OT,,,,,,,,,150591861,1,HIV infection
15059187,150591871,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058323,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591871,OT,,,,,,,,,150591871,1,HIV infection
15059190,150591901,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-055471,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150591901,OT,,,,,,,,,150591901,1,HIV infection
15059510,150595101,1,I,20171115,20180620,20180625,20180625,EXP,,PHHY2018LS028629,NOVARTIS,,87,YR,,M,Y,51,KG,20180625,,CN,LS,LS,EFAVIRENZ.,Acute kidney injury;Anaemia;Arthralgia;Asthenia;Death;Dry skin;Hyponatraemia;Hypothyroidism;Vomiting,150595101,HO,,,150595101,2,20171103,20171122,,,150595101,1,Tuberculosis
15060777,150607771,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058327,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607771,OT,,,,,,,,,150607771,1,HIV infection
15060778,150607781,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058329,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607781,OT,,,,,,,,,150607781,1,HIV infection
15060779,150607791,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058328,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607791,OT,,,,,,,,,150607791,1,HIV infection
15060780,150607801,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058330,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy,150607801,OT,,,,,,,,,150607801,1,HIV infection
15061538,150615381,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058332,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,150615381,DE,,,,,,,,,150615381,1,Product used for unknown indication
15061604,150616041,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058331,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,150616041,DE,,,,,,,,,150616041,1,Product used for unknown indication
15061606,150616061,1,I,,20180612,20180625,20180625,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-058333,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20180625,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,150616061,OT,,,,,,,,,150616061,1,Product used for unknown indication
15065451,150654511,1,I,,20180613,20180626,20180626,EXP,,IT-ROCHE-2141542,ROCHE,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS. ITALIAN JOURNAL OF PEDIATRICS. 2018;44 (37):-.",18,YR,,F,Y,,,20180626,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,150654511,OT,,,,,,,,,150654511,1,HIV infection
15066142,150661421,1,I,,20171127,20180626,20180626,EXP,,IT-AUROBINDO-AUR-APL-2017-45042,AUROBINDO,,27,YR,,F,Y,,,20180626,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,150661421,OT,,,,,,,,,150661421,1,Antiretroviral therapy
15077444,150774441,1,I,,20180619,20180627,20180627,EXP,,US-BAYER-2018-117301,BAYER,,44,YR,A,M,Y,46.98,KG,20180627,,MD,JP,US,EFAVIRENZ.,Abdominal distension;Confusional state;General physical health deterioration;Infection;Pancytopenia;Progressive multifocal leukoencephalopathy;Renal injury;Respiratory failure;Vomiting,150774441,OT,,,150774441,1,20180321,20180323,,,150774441,1,Tuberculosis
15081364,150813641,1,I,,20180625,20180628,20180628,EXP,,BR-STRIDES ARCOLAB LIMITED-2018SP005314,STRIDES,,,,,,Y,,,20180628,,CN,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby,150813641,OT,,,,,,,,,150813641,1,Product used for unknown indication
15103723,151037231,1,I,20180601,,20180611,20180611,DIR,,,FDA-CTU,,42,YR,,M,N,,,20180611,N,PH,US,US,EFAVIRENZ TAB 600MG,Cheilitis,,,151037231,HP,151037231,1,20180328,20180611,,,,,
6650762,66507623,3,F,20080424,20180606,20080528,20180611,EXP,,FR-GILEAD-2008-0016477,GILEAD,,31,YR,A,F,Y,,,20180611,,MD,FR,FR,SUSTIVA,Blood lactate dehydrogenase increased;Erythema;Eyelid oedema;Nausea;Pyrexia;Rash maculo-papular;Toxic skin eruption;Transaminases increased,66507623,OT,,,66507623,1,20080418,20080424,,,66507623,1,HIV infection
6870591,68705913,3,F,,20170823,20081231,20180615,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14455729,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20180615,,CN,US,CA,SUSTIVA,Depression;Drug interaction,68705913,OT,,,68705913,1,2004,,,,68705913,1,Product used for unknown indication
7912876,79128762,2,F,,20180604,20110425,20180605,EXP,,GB-JNJFOC-20110408880,JANSSEN,"WOODCOCK H, NELSON M. BURKITT^S NON-HODGKINS LYMPHOMA PRESENTING AS FACIAL NERVE PALSY IN HIV-POSITIVE PATIENTS. INTERNATIONAL JOURNAL OF STD AND AIDS 2011;22:112-114.",55,YR,A,M,Y,,,20180605,,OT,GB,GB,EFAVIRENZ.,Off label use;Product use in unapproved indication;Toxicity to various agents,79128762,DE,,,,,,,,,79128762,1,Burkitt's lymphoma
8917556,89175564,4,F,20120105,20180425,20121120,20180507,EXP,,JP-GILEAD-2012-0064712,GILEAD,,39,YR,A,M,Y,,,20180507,,OT,JP,JP,EFAVIRENZ.,Osteoporosis;Osteoporotic fracture,89175564,OT,,,89175564,1,20050621,,,,89175564,1,HIV infection
9823287,98232872,2,F,,20180514,20140116,20180523,PER,,US-009507513-1401USA003256,MERCK,,31,YR,,F,Y,,,20180523,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,,,,,,,98232872,1,HIV infection
